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Preface
Multiple sclerosis (MS) is one of the most common disease of the central nervous system
affecting young adults. MS affects indeed about 2 million of people of any age and gender
although it has a special preference for young people, for women and for those in northern lat-
itudes. MS symptoms can vary among patients including visual, motor, sensory and cognitive
deficit leading to significant impact on personal and social daily-life of patients.
Historically, MS has been described for the first time in 1868 by Jean-Martin Charcot, a profes-
sor at the university of Paris, who observed the characteristic scars or "plaques" of MS during
an autopsy. Seminal studies performed in the late 19th and early 20th centuries showed MS was
characterized by demyelinated lesions around veins and inflammatory activity. During the
20th century, the development of several scientific domains, such as biology, led to attribute
MS damage to a dysfunction of the immune system. Though the exact causes of MS remain
unclear, several treaments and therapies have been developped so far to attenuate neurologi-
cal damage by reducing the pathological immune response. In the 1980’s, the emergence of
Magnetic Resonance Technology provided images of MS pathology (focal "plaques") leading
to more rapid diagnosis and a better monitoring of the disease and treatment effects. The
development of Magnetic Resonance Imaging (MRI) provided new insights on the changes due
to MS in the whole-brain, which included cortical and subcortical gray matter in addition to
the classical white matter "plaques". Furthermore, it became clear that the normal appearing
tissue was also alterated in MS patietns compared to healthy population.
Nowadays, MRI is a fundamental part of MS diagnosis and is mainly used for lesions detection
and qualitative estimation of lesions volume. However, though advances in conventional MRI
improved images sensitivity to measure mechanisms such as inflammation or tissue loss, they
lack of sensitivity to detect diffuse pathology and suffer from a poor correlation with clinical
symptoms. In this context, in the last decades new advanced techniques have emerged such
as diffusion imaging, relaxometry, magnetization transfer imaging and magnetic resonance
spectroscopy, providing more specific and sensitive tools to assess diffuse pathology. And
recently, it became clear that the combination of different MR contrasts or modalities would
improve our understanding of the underlying processes leading to neurodegeneration.
This dissertation presents a new approach combining several advanced MRI techniques to
study the overall effects of MS pathology in brain tissue at early stages of the disease. We
performed an extensive analysis to detect and identify diffuse and focal changes in normal ap-
pearing tissue, MS lesions and basal ganglia, but also to reveal the dynamics of these changes
in these regions.
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Preface
The pathogenesis of MS is very complex and multifactorial, with both genetic susceptibility
and environemental causes involved. Although they remain unclear, we know that these causes
lead to the propagation of the immune response and provokes brain damage observed in MRI.
In the first chapter, we briefly describe the MS pathogenesis and the different courses of the
disease, as well as the role of conventional and non-conventional MRI in our understanding
of MS pathology.
In Chapter 2, we present our approach combining relaxometry and magnetization transfer
imaging to detect and identify subtle and diffuse tissue alteration in MS patients. We per-
formed a comparative analysis on a group of relapsing-remitting MS patients with minor
deficit and a group of controls. We also correlate our MRI observations with clinical symptoms
characterized by motor and cognitive scores.
In Chapter 3, we used our approach to classify MS lesions according to the different mecha-
nisms occuring in these plaques.
In the Chapter 4, we focused on basal ganglia by using a new technique to estimate the partial
volume. The deep gray matter nuclei are indeed very challenging regions considering the
presence of mixture of brain tissue. Therefore, we propose to measure the proportion of
tissue in each voxel and to extract their characteristic MR signal in order to provide additional
information on the altered tissue.
Finally, the Chapter 5 present the results of a longitudinal study performed over 2 years. We
measured the dynamics of MS mechanisms in the normal appearing tissue and MS lesions
based on multi-contrast analysis. Last, we exploit the information of advanced MRI to predict
patients clinical outcome at 2 years follow up.
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Abstract
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults
around the world, affecting about 2 million of people of any age and gender. Typical symptoms
can vary among patients and include visual, motor, sensory and cognitive deficits which may
significantly impact patients personal and social life. Described for the first time in 1868
by Jean-Martin Charcot, MS has been intensely studied since then and is now defined as
a chronic inflammatory autoimmune demyelinating disease of the central nervous system.
In the 1980’s, the emergence of Magnetic Resonance Technology provided new insights on
brain pathology in MS, and improved the monitoring of available pharmacological therapies.
Nowadays, magnetic resonance imaging (MRI) is a fundamental part of MS diagnosis, and in
the last decades new advanced MRI techniques have emerged providing more specific and
sensitive tools to assess not only local pathology (plaques) but also diffuse alteration in the
brain tissue.
In this thesis, we present an approach combining new advanced MRI techniques including
relaxometry and magnetization transfer imaging, to analyse brain tissue micro-structure prop-
erties in MS patients. We show how to take advantage of the complementarity of quantitative
and semi-quantitative MRI sensitivity, to identify the physio-pathological processes under-
lying tissue alterations in normal appearing tissue, MS lesions and deep gray matter nuclei.
We then extend our multi-contrast approach to model the heterogeneity of tissue damage in
MS lesions through a classification framework, and present an innovative technique based on
partial volume estimation, to provide additional information on the micro-properties of the
tissue in thalamus and basal ganglia. Last, we show the potential of our approach to monitor
MS disease over time, and to identify complex mechanisms such as repair and degeneration
activity.
Our work provides evidence of the potential of multi-contrast advanced MRI to study the
physiopathology of MS over the whole brain, even at early stages of the disease. Though
these state-of-the art MRI techniques require more sophisticated hardware and software than
conventional MRI, recent advances in acquisitions speed and robustness render them strong
candidates for clinical applications in next future.
Key words: Multiple Sclerosis, Advanced MRI, Quantitative imaging techniques, Micro-
structure analysis, Multi-contrast.
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Résumé
La Sclérose en Plaques (SEP) est la maladie neurologique chez les jeunes adultes la plus com-
mune dans le monde, touchant 2 millions de personnes de tout age et genre. Les symptômes
classiques peuvent varier parmi les patients incluant des déficits visuel, moteur, sensoriel et
cognitif qui ont un impact significatif sur leur quotidien et leur vie sociale. Décrites pour la
première fois en 1868 par Jean-Martin Charcot, la SEP, qui a été depuis intensément étudié, est
une maladie auto-immune et inflammatoire chronique affectant le système nerveux central.
Dans les années 1980, l’émergence de la technologie de résonance magnétique a fourni une
nouvelle vision des modifications du tissue cérébral provoqués par la maladie, et a amélioré le
suivi des traitements et des thérapies développées jusqu’alors. De nos jours, l’Imagerie par
Résonance Magnétique (IRM) est devenue fondamentale lors du diagnostique de la SEP, de
plus ces dernières années l’émergence de nouvelles techniques avancées a permis le develo-
pement d’analyses plus spécifiques et sensibles aux pathologies diffuse de la SEP.
Dans cette thèse, nous présentons une nouvelle approche combinant de nouvelles techniques
avancées d’imagerie dont la relaxometrie et l’imagerie par transfert magnétique, afin d’analy-
ser les propriétés micro-structurelles du tissue cérébral chez les personnes atteintes de SEP.
Nous montrons comment profiter de la complémentarité des contrastes IRM pour identifier
les processus physiopathologiques sous-jacents dans les tissue d’apparence normale, les
lésions et les noyaux gris. Nous étendons ensuite notre approche en modélisant l’hétérogé-
néité des lésions de la SEP à l’aide d’une méthode de classification, puis nous présentons
une technique innovante basée sur l’estimation du volume partiel qui fourni de nouvelles
informations sur la microstructure du thalamus et des noyaux gris centraux. Enfin, ces travaux
révèlent le potentiel de notre approche pour assurer le suivi de la maladie, et ainsi identifier
des mécanismes complexes tels que la dégénérescence et la capacité de réparation du cerveau.
En conclusion, nos travaux prouvent le potentiel de ses nouvelles techniques IRM pour étudier
la physiopathologie de la SEP dans toutes les parties du cerveau, même aux premiers stades
de la maladie. Bien que ces nouvelles techniques d’acquisition requièrent des méthodes de
traitement plus sophistiquées, les récentes avancées en termes de rapidité et de robustesse
des acquisitions IRM en font de sérieux candidats pour les applications cliniques des années à
venir.
Mots clefs : Sclérose en Plaques, IRM avancé, Techniques d’imagerie quantitative, Analyse de
la micro-structure, Multi-contrast.
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1 Neuromaging in Multiple Sclerosis
1.1 Introduction
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults
around the world. MS affects about 2 million of people of any age and gender, though it’s most
commonly diagnosed in women between the age of 20 and 50 years [1]. Typical symptoms
include visual, motor, sensory and cognitive deficits as well as fatigue, leading to physical and
cognitive disability. Therefore, MS has a significant personal, social and economic impact for
patients and healthcare services. MS is a chronic inflammatory autoimmune demyelinating
disease of the central nervous system (CNS). It affects the brain and the spinal cord through
focal and diffuse alteration of brain tissue. Traditionally, MS has been characterized by the
presence of focal demyelination; yet in the last decades, magnetic resonance imaging (MRI)
studies revealed substantial cortical damage as well as diffuse changes in normal appearing
(NA) tissue. Although MRI provided new insight in the physiopathology of MS, the underlying
mechanisms of brain degeneration remain unclear. The recent development of advanced MR
techniques such as T1, T2, T2* relaxometry ,magnetisation transfer imaging, diffusion imaging
and spectroscopy may provide new and sensitive ways to characterize tissue biology and
pathology in vivo in MS, in order to improve diagnostic, prognostic and follow-up methods.
1.2 Multiple sclerosis
1.2.1 Pathogenesis of MS
MS pathophysiology is complex and multifactorial. In fact, both genetic susceptibility and
environmental factors contribute to the development of MS in a complex interplay. In an
initial step, inflammatory cells cross into the CNS due to blood brain barrier leaks [2],then
the immune response is propagated through the brain. A non specific immune response, the
innate response, provokes first the production of small proteins so-called cytokines, which
modulate an adaptive immune response [3]. The innate system plays a role both in the
initiation and progression of MS by influencing the effector function of specialised defender
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cells: the T and B cells. The adaptive response is in fact initiated by the presentation of a
specific antigen to T lymphocytes using antigen presenting cells such as B cells, dendritic cells,
microglia and macrophages. The propagation of these molecules and cytokines promotes
inflammatory process and induce demyelination. Some studies observed a positive correlation
of T-cells, macrophages and microglia with the extent of axonal damage [4], [5]. These results
suggest that the myelin breakdown leaves axons vulnerable to pro-inflammatory mediators
direct attacks. Myelin loss may also contribute to the disease process by activating microglia,
which mediate neuronal damage [6]. There is also evidence that the loss of oligodentrocytes
which provide trophic support to axons, leads to degeneration despite intact surrounding
myelin and a lack of inflammation [7], [8]. These damages manifest by the appearance of focal
lesions, which develop around small veins and venules in several regions of the brain, with
a variable degree of inflammation, gliosis and axonal degeneration [9]. In addition to this
degenerative aspect, the presence of newly formed myelin indicates signs of remyelination in
MS lesions reflecting brain plasticity [10]. In the last decade, cortical demyelination has also
emerged as a critical aspect of the pathogenesis of MS [11–14], as well as diffuse inflammation
[15] and progressive neuroaxonal loss in NA tissue [7]. The complex interaction and overlap of
these underlying processes induced by immune-mediated renders the clinical disease course
of MS difficult to monitor and predict.
1.2.2 Clinical onset and diagnosis
Inflammatory and neurodegenerative processes in MS lead to physical and cognitive dis-
abilities. MS symptoms can vary among patients and include muscle weakness, balance
problems, loss of coordination and mobility, visual and sensory problems, speech difficulties,
bowel, bladder and sexual dysfunction, as well as cognitive impairment. In this context, early
diagnosis is important since treatment can slow the disease, improve patient daily life and
decrease long-term disability. To date, MS is diagnosed based on the revised McDonald criteria
2010 [16], which rely on clinical and MRI data. These tests are based on the principles of
dissemination in space (DIS) and dissemination in time (DIT) of the disease, and the exclusion
of other diseases with similar characteristics. DIS and DIT are established using serial MR
images. They allow to predict clinically definite MS diagnosis in 70% of patients who have
experienced only a single clinically isolated syndrome (CIS) [17]. Recently, new guidelines
have proposed to diagnose MS in a CIS patient using a single MRI scan [18].
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Clinical
(attack)
Lesions Additional criteria
2 or more
Objective clinical evidence of more than 2
lesions or objective clinical evidence of 1
lesion with reasonable historical evidence
of a prior attack
None. Clinical evidence alone will suffice,
additional evidence desirable but must be
consistent with MS
2 or more Objective clinical evidence of 1 lesion
DIS; OR await further clinical attack
implicating a different CNS site
1 Objective evidence of at least 2 lesions DIT; OR await a second clinical attack
1 Objective clinical evidence of 1 lesion
DIS; OR await further clinical attack
implicating a different CNS site AND DIT;
OR await a second clinical attack
0 (progres-
sion from
onset)
One year of disease progression
(retrospective or prospective) AND at
least two of : DIS in the brain based on at
least 1 T2 lesion in periventricular,
juxtacortical or infratentorial regions; DIS
in the spinal cord based on at least 2
lesions or positive CSF
Table 1.1: 2010 revised McDonald MS diagnostic criteria. The diagnosis of MS requires
elimination of more likely diagnose and demonstration of dissemination of lesions in space
(DIS) and time (DIT).
1.2.3 MS subtypes
The complex pathogenesis of MS and the variety of symptoms among patients, make the
clinical disease course of MS unpredictable. To date, four different clinical MS forms have
been described (see Figure 1.1) [19]:
• Relapsing remitting (RRMS) affects 85% of MS patients and is characterized by episodes
of exacerbations of symptoms followed by periods of remission.
• Secondary progressive (SPMS) develops in more than 50% of untreated patients affected
by RRMS. The course of the disease continues to worsen with or without periods of
remission or levelling of symptoms severity.
• Primary progressive (PPMS) is a form of MS which is more resistant to drugs typically
used in MS therapy. The symptoms continue to worsen gradually without remission or
relapse episodes with occasional plateaus. However few MS patients are affected by this
subtype ( 10%).
• Progressive relapsing MD (PRMS) is the rarest form of MS (<5%). Its course is progressive
3
Chapter 1. Neuromaging in Multiple Sclerosis
from the start without any period of remission.
The disease progression is usually assessed by neurological examination and disability rating
scales such as the Expended Disability Status Scale (EDSS) [20]. Nevertheless, these methods
lack of sensitivity and specificity to monitor the disease course on short period of time. In this
context, magnetic resonance imaging is an objective and sensitive tool, which may provide
appropriate and reliable criteria to diagnose and monitor disease progression.
Figure 1.1: Clinical course of MS subtypes.
1.3 Magnetic Resonance Imaging in Multiple Sclerosis
Magnetic resonance imaging (MRI) plays an important role both for MS clinical management
and the investigation of its physiopathology. Conventional MRI techniques are routinely used
for MS clinical diagnosis and patients follow-up. Nevertheless, they suffer from a number
of limitations such as limited sensitivity to diffuse damage as well as low correlations with
clinical tests. In this context, new emerging techniques such as diffusion imaging, relaxometry
or magnetization transfer imaging propose a novel approach to assess at a time focal and
diffuse pathology and support with new biomarkers correlating with clinical performances.
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1.3.1 Conventional MRI in MS
Conventional MRI (cMRI) techniques are sequences used routinely on a standard clinical
MRI scanner. In MS, they are mainly used for lesion detection and monitoring, but also
for qualitative atrophy measurements. These sequences include proton density (PD), T2-
weighted (T2-w), T1-weighted (T1-w), Fluid Attenuated Inversion Recovery (FLAIR) images
and Gadolinium-enhanced T1-weighted imaging. Conventional MRI techniques have been
developed to improve diagnosis and prognosis in MS by revealing mainly focal expression
of MS pathology. Although to date, atrophy measurement are not a part of clinical routine,
recent improvements in cMRI post-processing methods allow to perform off-line longitudinal
volumetric analysis and atrophy rates of specific brain structures or the whole brain.
Conventional MR physics
MR technology is based on nuclear magnetic resonance of atoms within the body induced by
the application of radio waves. The signal intensity on an MR image is determined by basic
parameters characterizing tissue properties: the proton density (PD), and the relaxation times
T1, T2 and T2*. The proton density is the concentration of protons in the tissue in the form
of water and macromolecules (proteins, macrophages, etc). The relaxation times T1, T2 and
T2* define the way that the protons revert back to their resting states after the initial RF pulse.
They are representatives of the structural characteristics of the tissue. T1, T2 and PD weighted
images are basic pulse sequences in MRI and are widely used in clinical application of MS.
Recently, the FLAIR sequence has replaced the PD image. FLAIR images are T2-w with the CSF
signal suppressed (see Figure 1.2). Recent improvements in MR field also allowed to provide
high resolution (1mm3) images at high field (3T), and improve detection and identification of
pathology of MS in the brain.
Focal inflammation and neurodegeneration in conventional MRI
cMRI allows visualisation of the structure of the brain, and the areas of focal damage due
to the increased water content relative to the surrounding tissue. PD and T2-w images are
standard sequences in clinical practice to detect MS lesions which appear as focal areas of
signal increase. MS lesions observed from these sequences can occur throughout the entire
CNS, but tend to predominate in the periventricular WM. In this area, due to the suppression of
CSF signal in FLAIR, the lesions can be better distinguished from CSF spaces than in PD/T2-w
images. T1-w images are mainly used to differentiate anatomical structures thanks to the high
contrast between each tissue, where high proton density areas appear bright and low density
dark. On T1-w images increased water such as oedema appear as hypointense. However, only
10-30% of lesions seen on T2-w images can be visualised on T1-w images, which suggests
that these T2-w lesions invisible on T1-w may reflect inflammatory process. On the opposite
side, the chronic T1 hypointensities so-called "black holes" indicate areas with severe tissue
destruction which may reflect marked oedema with or without matrix destruction during
acute phase of MS [21, 22]. During the active stage of MS, there is an increased permeability of
the blood brain barrier and the contrast agent Gadolinium (Gd) is used with T1-w imaging to
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identify areas of acute inflammation and distinguish active and inactive lesions. T1-w is indeed
sensitive to paramagnetic substances such as Gd which appear bright. Gd-enhanced T1-w
images provide an important tool to detect and distinguish acute/active and chronic/non-
active lesions, but this method remain invasive and strongly affected by several factors such as
Gd dose, image acquisition parameters and treatment during acute attacks [23].
Figure 1.2: T1-w MPRAGE, T2-w FLAIR of MS patients with lesions (red arrows). Lesion appear
brighter on T2-w images, and darker on T1-w images.
Recently, new approaches using cMRI have emerged based on serial analysis of images [24] or
their substraction [25], to relate signal changes to lesions evolution.
Global neurodegeneration in conventional MRI
Cerebral atrophy is a common feature of MS reflecting loss of neurons and the connections
between them. Atrophy can be generalized or focal. In the last decade, brain volumetry has
become an emerging technique based on conventional MRI data to provide sensitive and
reproducible assessments of brain volumetry over time and hence atrophy rates. Several
methods exist to assess brain atrophy based on segmentation or registration techniques
[26, 27]. Although it has been recognised as a feature of advanced or severe MS, some studies
measured atrophy already in CIS and early stage patients [27]. A number of gray and white
matter (WM) regions are affected by atrophy such as cerebral lobes, brainstem, cerebellum,
thalamus and specific WM tracts [28]. Recent studies evidenced gray matter (GM) atrophy
expressed by diffuse and focal thinning of cortex [29, 30]. A small cohort study showed
cortical thinning in frontal and temporal cortex of early disease or mild disability patients [29]
and a larger study reported significant correlations between cortical atrophy in the anterior
cingulate cortex, insula and temporal gyrus with lesion load [30]. Cortical atrophy has also
been shown to be the best predictor of future disability in MS patients [28,31]. Despite atrophy
is related to neurodegeneration, the underlying mechanisms appear to differ depending
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on its location. Inflammation appeared more pronounced in WM areas compared with GM
areas [28,32]. This suggest that atrophy in WM is mainly reflecting focal loss of myelin and axon
following inflammation [28, 33, 34]. Yet, a longitudinal study suggested that WM volume may
transiently increase due to presence of oedema, despite an increase of lesion load, masking
sometimes the real brain volume loss [35]. Conventional MRI techniques provide measures
of inflammation (T2-w lesions, gadolinium-enhancing T1-w lesions), in acute and chronic
disease, and new post-processing methods applied to conventional sequences support with
measures of degeneration (global brain atrophy) as well as with metrics of focal tissue loss
(chronic black holes on T1-w images). Combined, they provide a unique insight into the
dynamics of MS lesion development and the long-term pathological consequences on CNS
tissues. However, cMRI showed weak associations with clinical status which may reflect its
lack of sensitivity to detect diffuse disease. In this context, non-conventional techniques have
emerged and may improve the detection of diffuse MS pathology and the correlation with
clinical disabilities.
1.3.2 Non-conventionall MRI in MS
Non-conventional quantitative MRI techniques (qMRI) have raised in the last decades, and
provided new insights into MS pathology. The signal intensity in conventional MRI is influ-
enced by intrinsic contrast mechanisms, such as density of water proton and proton relaxation
(T1, T2, T2*), but also by characteristics unrelated to tissue properties such as scan parameters,
variation in the magnetic field and image scaling [36]. Quantitative imaging provides infor-
mation on the tissue properties that is theoretically independent of hardware and sequence
parameters. Quantification, therefore, allows comparisons across different sites, between
different patients and different time-points [37]. In addition, qMRI provide biophysical pa-
rameters maps which are more specific for the microscopic structure of tissue than the mixed
contrast images of conventional MRI. Advanced MR sequences require more sophisticated
methods and post-processing approaches to compute parameters maps, which limit their use
to research field. However recent advances in acquisition speed and robustness make them
more suitable to clinical applications.
Relaxometry
Magnetic resonance relaxometry is a promising approach to assess tissue properties and
composition in vivo. This quantitative method provides a more detailed characterization
of tissue microstructure by establishing a more direct link between MRI signal and tissue
microstructural properties. The term microstructure comprise neuronal bodies, unmyeli-
nated and myelinated axons, glia cells, vessels, and extracellular-extravascular spaces. The
biophysical parameters related to MR sequences are the proton density and the relaxation
times T1, T2 and T2*.
T1 relaxation time (T1-rt) in brain tissue is mainly influenced by free water protons and the
degree of structural organization (i.e. amount of macromolecules such as myelin, lipids,
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proteins). Myelin shortens T1 as the lipid composing myelin sheath do not contribute to
signal. In this context, an increase in T1-rt may indicate a loss of structure or myelin and/or
an increase in water content (see Figure 1.3). Conversely, greater density of macromolecules
and reduced water content as well as iron accumulation tend to reduce T1 [38].
T2-rt measures the loss of spin coherence and therefore, mainly reflect the dynamic state of
water protons and their interaction with macromolecules. An increase in T2-rt characterizes a
loss of macromolecules and/or increased water content. On the contrary, a decrease in T2-rt
reflects an increase of protons bound to macromolecules. As for T1, iron accumulation also
causes a shorter T2 [39] (see Figure 1.3).
The effective T2*-rt transverse describes the loss of transverse magnetization due to T2 re-
laxation and magnetic field inhomogeneities (R2’ component [40]). Possible sources are
tissue-dependent differences in magnetic susceptibility or the presence of paramagnetic or
ferromagnetic ions like iron. For these reasons, an increase in T2* most often indicates a loss
of macromolecules, while a decrease suggests an increase of macromolecular compounds or
iron that translate into an increase in R2’.
Figure 1.3: T1, T2 and MTR images of MS patients with lesions. On T1 and T2 quantitative
maps, lesion appears bright while it appears darker on MTR image.
In the last decades, single scan relaxometry acquisitions have been extensively used in MS
research (for review see [41, 42]). Several studies used quantitative imaging to assess diffuse
processes such as inflammation and degeneration in normal-appearing (NA) tissue in MS
patients. Neema and Whittall observed an increase of the T2-rt in the normal appearing
white matter (NAWM) of a heterogeneous cohort of MS patients compared to healthy controls
[43, 44], while Bakshi showed T2 increase in the deep GM [45]. These findings suggest diffuse
inflammatory process in NA tissue. On the other hand, Vrenken used T1 mapping to observe
global changes in the NA gray and WM in RR and SP MS patients with long disease duration [46],
and Manfredonia et al. investigated global T1 changes in early stages of the disease and their
correlation with disability [47]. The prolongation of T1-rt due to tissue or axonal/myelin loss
appeared less pronounced compared to inflammation [48]. In addition, T1rt is more affected
(longer) by axonal loss than myelin loss. Therefore, previous results reporting prolongation of
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T1-rt in NAWM and NAGM as well as WM/GM lesions might indicate the presence of different
degrees of inflammation or degeneration.
Magnetization transfer imaging
Magnetization transfer (MT) imaging targets cross-relaxation and exchange between macro-
molecules and water. MT contrast is evoked by implementing additional off-resonance radio-
frequency RF pulses into MRI sequences. Such an MT pulse reduces the longitudinal magneti-
zation of the macromolecules, but has little effect on the free water. This saturation is then
transferred to the water [49] and observed as an attenuated signal compared to the absence of
pulses. In vivo MT measurements are quantified by a two pool model. Most relevant parame-
ters are the macromolecular fraction and the forward transfer rate. The bound pool is larger in
WM (11%) than in GM (4%), much smaller in blood, and practically absent in cerebro-spinal
fluid (CSF) [50] (see Figure 1.3). Several metrics can be obtained from MTI scans. The first
analysis step is the creation of MTR maps, derived from the two sets of images acquired with
and without off resonance pulse. The MT ratio are derived by removing the signal of the free
protons voxel-by-voxel according to the equation :
MT R =
M0−MT
M0
(1.1)
with M0 and MT the T2* images acquired without and with MT pulse, respectively. MTR
expresses macromolecular tissue integrity and provides both morphological and pathological
information with a higher specificity than conventional MRI [51].
MT ratio which informs about myelin integrity and water content [52], has been widely used
to perform histogram analysis of NA tissue in MS patients. Despites a limited difference found
by Vrenken in MTR measure of NA tissue between controls and MS patients [53], Catalaa
and others found a significant decrease of MTR in NA tissue of MS subjects compared to
healthy controls [54]. Levesque and Tardif also used MTR to analyze lesion tissue in MS
patients and observed a lower MTR in both subcortical and cortical lesions compared to
healthy tissue [55, 56]. In all these studies, relative MTR decrease has been interpreted as the
result of myelin loss. Nevertheless, inflammation and oedema also influence MTR [52], and
should be take into account when interpreting MTR images.
Diffusion imaging
Diffusion imaging is based on the microscopic Brownian motion of water molecules. In a tissue,
diffusion is ’hindered’ by the semipermeable cell membranes, which couple the diffusivity
in extra- and intracellular subspaces. In the axon bundles of WM, diffusion is anisotropic.
The simplest model to describe the directional dependence of diffusion is an ellipsoid, the
diffusion tensor (DT) [57]. The main diffusion direction is that along the parallel axons. The
mean diffusion over all directions is mean diffusivity (MD). The degree of anisotropy is a
scalar measure for axonal coherence, and is known as the fractional anisotropy (FA). Increased
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MD and reduced FA are the hallmarks of demyelination. Pathological studies evaluated the
physiological correlates of these diffusion indices [58], and a post-mortem study showed
strong correlation between MD and FA with myelin content in chronic MS patients [59].
Abnormalities in diffusivity patterns have been observed in focal MS lesion and NA brain
tissue (NABT). Several studies showed increase of MD and decrease of FA at various degrees in
lesions compare with NABT [60, 61]. An histopathological study showed that MD reflects the
advanced alteration of the tissue in chronic T1 hypointensities, where there is an irreversible
tissue disruption, gliosis and axonal loss [21]. Conversely, a longitudinal study in patient
revealed a progressive increase of MD only in a subgroup of Gd-enhancing lesions which were
all showing MD increase at the beginning [62]. These results suggest that MD is sensitive
to the different mechanisms in MS lesions such as neurodegeneration but also oedema,
demyelination and remyelination. Unlike MD, FA appears higher in non-enhancing of lesions
compared with Gd-enhancing lesions, reflecting a sensitivity to demyelination, axonal injury
and large amount of inflammatory cells [61, 63]. Diffusion imaging provided also new insights
on diffuse pathology in NABT. Several studies found abnormalities in diffusion metrics in the
periphery of T2 lesions in the NAWM and NAGM, as well as in regions of NAWM close to newly
appeared lesions [61, 64]. Global analysis also reported higher average MD and lower average
FA in MS patients compared with healthy controls [65]. Diffusion tensor imaging properties,
such as mean brain diffusity or apparent diffusion coefficient in NABT and lesions, have also
been suggested as strong predictors of clinical outcome [66]. Correlation between diffusion
metrics in T2 lesions and disability were observed [67].
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) complements magnetic resonance imaging (MRI) as
a non-invasive technique. Proton MRS uses the signal from hydrogen protons to determine the
concentration of brain metabolites such as N-acetyl aspartate (NAA), choline (Cho), creatine
(Cr) and lactate in the tissue examined. Hydrogen MRS has now become a routinely used
clinical tool in the brain, and is widely used to study MS as it proposes potential specific
biomarkers of demyelination, inflammation and neuronal/axonal integrity [68]. NAA, found
exclusively in neurons, is a marker of neuronal viability and its decrease may reflect inflamma-
tory conditions but also axonal or neuronal loss. Cho resonance have been associated with a
protein expressing cells proliferation, and is also an important indicator, with Cr, of disease
state such as demyelination. Lactate is absent in normal brain tissue and its presence is indica-
tive of metabolic disorders. The combination of these different measurements provide specific
information on the nature of mechanisms underlying brain tissue alteration. MRS studies
showed indeed a diminished NAA peak and increased Cho and free-lipid peaks in acute MS
lesions, suggesting demyelination and axonal loss [69–71]. The MRS was also used to evaluate
neuronal damage in NAWM, where lower NAA-Cr ratio in patients was observed [69, 72]. In
addition, correlations with clinical disability showed that MRS metabolic measurements were
better predictors than conventional MRI [72, 73].
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1.3.3 Mulitmodal approach
THe brain quantitative imaging techniques detailed above provide complementary informa-
tion that is critical to understand the complexity of MS physiopathology. However, to date,
most qMRI studies applied a single contrast approach, which leads to important limitations
when the results need to be interpreted [74]. In fact unicontrastl studies can not discriminate
single underlying mechanism. For example, magnetization transfer imaging alone cannot
discriminate between myelin alterations and variation of water content in tissues [52].As
another example, DTI studies showed reduced fractional anisotropy (FA) in NAWM of early
MS patients that was interpreted as axonal loss [75, 76]. Nevertheless, this interpretation
may be misleading since loss of anisotropy can derive from the loss of the branched-shape
of microglia cells that is typical of their activated-inflammatory form [77]. Thus, another
possible explanation is that reduced FA might point to inflammatory rather than degenerative
phenomena. In the last five years, multimodal approaches in MRI have become a popular
moethod to study pathophysiology of neurodegenerative disease. The combination of differ-
ent MR modalities or contrasts provided MR parameters sensitive to complementary tissue
characteristics (atrophy, iron, microstructure damage...) which have a great potential to detect
and identify pathological changes. In addition, multi-contrast approaches also show strong
potential to improve disability prediction.
In MS, a number of studies tried to address the limitation of unicontrast ones by combining
relaxometry, MTR measurements [78], and DTI [79]. Hasan et al. used T2 relaxometry and
diffusion tractography maps to assess widespread pathology of RRMS patients. They focused
their analysis on neocortical and corpus callosum regions, and observed increase in T2 and
diffusivities suggesting inflammation. Their multimodal approach also improve correlation
with disability scores [79]. In another study, Reich et al. proposed a multi-contrast approach
associating relaxometry, diffusion and magnetization transfer imaging. They analysed the
corticospinal tract of advanced MS patients, and found abnormalities along this tract such as
MTR decreases or asymmetry [78].
1.3.4 Conclusion
MRI plays now a key role in the diagnosis and monitoring of MS by characterizing brain tissue
properties in vivo and reducing the gap with clinical findings. The complex mechanisms
underlying MS pathology are still unclear, but the ongoing advances in MRI technology
should extend our understanding of disease effects on tissue microstructure. In this thesis, we
combined advanced MRI techniques, including relaxometry, magnetization transfer imaging
and new imaging techniques such as 3D Fluid Attenuated Inversion Recovery (FLAIR) and
Double Inversion Recovery (DIR) sequences, to assess brain tissue microstructure properties
of MS patients at early stage of the disease. We performed our analysis on NA tissue, MS lesions,
but also focused on deep GM structures. In the next chapter, we present our multi-contrast
approach applied to analyse diffuse changes in NA tissue.
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2 Multi-contrast MRI for normal ap-
pearing tissue analysis
Abstract
In patients with multiple sclerosis (MS), conventional magnetic resonance imaging (MRI) pro-
vides only limited insights into the nature of brain damage with modest clinical-radiological
correlation. In this chapter, we applied recent advanced MRI techniques to study brain micro-
structural alterations in a early relapsing-remitting MS (RRMS) patients cohort with minor
deficits. Further, we investigated the potential use of advanced MRI to predict functional
performances in these patients. Brain relaxometry (T1, T2, T2*) and magnetisation transfer
imaging were performed at 3T in 36 RRMS patients and 18 healthy controls (HC). Multi-
contrast analysis was used to assess for micro-structural alterations in normal-appearing (NA)
tissue and lesions. A generalized linear model was computed to predict clinical performance
in patients using multi-contrast MRI data, conventional MRI measures as well as demographic
and behavioural data as covariates. Results showed that quantitative T2 and T2* relaxometry
were significantly increased in temporal normal appearing white matter (NAWM) of patients
compared to HC, indicating subtle micro-edema (T2 : p = 0.03; T2* : p = 0.004). Furthermore,
significant T1 and magnetisation transfer ratio (MTR) variations in lesions (mean T1 z-score:
4.42 and mean MTR z-score: -4.09) suggested substantial tissue loss. Finally, combinations of
multi-contrast and conventional MRI data significantly predicted cognitive fatigue (p = 0.01,
Adj-R2 = 0.4), attention (p = 0.0004, Adj-R2 = 0.6), and disability (p = 0.03, Adj-R2 = 0.4). In
conclusion, advanced MRI techniques at 3T unraveled the nature of brain tissue damage in
early MS and substantially improved clinical-radiological correlations in patients with minor
deficits, as compared to conventional measures of disease.
The content of this chapter has been published in [80].
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2.1 Introduction
MS is characterized by the presence of focal lesions in WM and GM, but also by diffuse inflam-
mation and degeneration in normal-appearing (NA) tissue [81, 82]. Conventional MRI, which
plays a major role in identifying focal inflammation and diagnosing MS, has important limits in
assessing underlying pathology. As a consequence, this method provides only modest correla-
tions with patient functional performance, particularly during early phases of the disease [41].
In this context, quantitative and semi-quantitative (q/sq) MRI techniques [42, 83] may provide
new biomarkers of disease severity and help to improve the clinical-radiological mismatch in
MS treatment. To this end, pathological processes such as demyelination, oedema formation,
tissue loss, and iron accumulation lead to variable changes in quantitative measures of proton
relaxation times (T1, T2, and T2*) as well as in semi-quantitative parameters such as the
magnetisation transfer ratio (MTR) [43,45,54–56]. Thanks to recent MRI developments [84,85],
it is now possible to combine multiple q/sq MRI sequences in a clinically applicable protocol
and gather more specific information about the nature of tissue pathology in MS.
In this chapter, we investigated whether the combination of advanced T1, T2, and T2* relax-
ometry and magnetisation transfer imaging may be employed (i) to assess the nature of brain
tissue changes occurring early in MS and (ii) to improve the correlation between imaging and
clinical performance.
2.2 Method
2.2.1 Study population
We enrolled 36 patients with relapsing-remitting MS (RRMS), 24 women / 12 men, age = 34.8
± 9.2 years (mean ± standard deviation (SD)) and 18 age-matched healthy controls (HC), 9
women / 9 men, age = 33 ± 9.7 years. All patients were < 6 years from initial symptoms (33.3
± 21 months, range 2 to 70 months) and disease diagnosis (27.1 ± 18 months, range 0 to 59
months) (see Table 2.1). Thirty patients (83%) were under immunomodulatory treatment (high
dosage IFN beta or fingolimod) for at least 3 months. No patient had received corticosteroid
therapy within the three months preceding the enrollment. The study was approved by the
ethics committee of the Lausanne University Hospital (CHUV). Written, informed consent
was obtained from each subject.
Demographic data HC RRMS patient
Number of subjects 18 36
Age (mean years ± std) 33 ± 9.7 34.8 ± 9.2
Gender(feamles:males) 9:9 24:12
Months since intial symptoms 27.1 ± 18
Table 2.1: Demographic characteristics of HC and RRMS patients.
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2.2.2 Clinical assessment
Each subject underwent a neurological examination including the following cognitive and
behavioural tests: (i) Brief Repeatable Battery of Neuropsychological Tests (BRB-N) [86], which
examine verbal and spatial memory, sustained attention, information processing speed, and
verbal fluency on semantic cues; (ii) the Hospital Anxiety and Depression scale (HAD) [87]
and (iii) the Fatigue Scale for Motor and Cognitive functions (FSMC) [88], which quantifies
depressive mood symptoms and fatigue. The Expanded Disability Status Scale (EDSS [20]) and
the Multiple Sclerosis Functional Composite (MSFC [89]) scores were assessed by a certified
neurologist (C. Granziera, CG) to quantify motor performance. (see Table 2.2).
Disability and
motor tests
Assessed function HC RRMS patient
BRB-N
SRT-LTS Verbal memory 66.06 ± 6.72 64.14± 7.12
SRT-CTLR Verbal memory 63.19 ± 8.76 59.64± 11.94
SRT-D Verbal memory 11.75 ± 1 11.54± 0.79
SDMT Attention 56.88 ± 12.24 58.54± 9.89
WLG Execution 27.56 ± 7.23 28.64± 5.65
Mood and fatigue
HADA Anxiety 5.38± 2.45 6.50± 4.32
HADD Depression 1.38± 1.26 3.07± 2.62
FSMC Cognitive Cognitive fatigue 16.13± 5.30 23.00± 9.17
FSMC motor Motor fatigue 14.19± 4.25 22.39± 11.01
EDSS Disability 1.55± 0.21
MSFC Disability -0.08± 0.24
Table 2.2: Clinical tests (mean ± std)
2.2.3 MRI techniques
All MR images were acquired on a 3T Siemens Trio (Siemens, Erlangen, Germany) equipped
with a 32-channel head coil. The acquisition protocol consisted of (see Table 2.3):
• High-resolution 3D magnetization-prepared acquisition with gradient echo (MPRAGE)
(TR/TE = 2300/2.89 ms, voxel size = 1.0x1.0x1.2 mm3, FoV = 256x240x192 mm3, ac-
quisition time = 5:12 min) for automatic brain tissue and atlas-based segmentation as
reported previously [90–92]; signal-to-noise ratio (SNR) measurements on a MPRAGE
image were performed based on [93, 94];
• High-resolution 3D fluid attenuated inversion recovery (FLAIR) (TR/TE/TI = 5000/394/1800
ms, voxel size = 1.0x1.0x1.2 mm3, FoV = 256x240x212 mm3, acquisition time = 6:27 min);
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• High-resolution 3D double inversion recovery (DIR) (TR/TE/TI = 10000/218/3650 ms,
voxel size = 1.1x1.0x1.2 mm3, FoV = 256x240x192 mm3, inversion times 450/3652 ms,
acquisition time = 12:52 min);
• Magnetization Prepared 2 Rapid Acquisition Gradient Echoes MP2RAGE [85] (TR/TE =
5000/2.89 ms, voxel size = 1x1x1.2 mm3, FoV = 256x240x192 mm3, acquisition time =
8:22 min) for lesion count [95] and whole-brain T1 relaxometry;
• T2 relaxometry (TR/TE = 5000/9 ms, 21 echos, 30 slices: voxel size = 1x1x4 mm3, FoV
= 256x240x192 mm3, acquisition time = 3 min) using a new nonlinear inverse recon-
struction algorithm that directly estimates a T2 and spin-density map from a train of
undersampled spin echoes [84];
• T2* relaxometry (TR/TE = 47/1.23 ms, 32 gradient echoes, voxel size = 1.6x1.6x1.6 mm3,
FoV = 217x217x179 mm3, acquisition time = 11:16 min) with and without magnetization
transfer (MT) pulse (MT pulse flip angle: 220 deg; duration: 4000 ms; pulse offset: 2000
Hz; spoiler moment: 25000 us*mT/m).
In order to correct for susceptibility induced macroscopic field inhomogeneities, which were
already diminished by isotropic high-spatial resolution, we used a 3D Sinc Correction [96] that
was extended to include a non-linear correction term based on the underlying B0 map [97];
The B0 map was calculated as the weighted mean phase difference [98] of the temporally
unwrapped phase followed by a median and Gaussian filters to remove phase inconsistencies
[99]. R2’ maps were computed from T2 and T2* maps according to
R2′ =
1
T 2∗−
1
T 2
(2.1)
MTR maps were derived from the T2* data by
MT R =
M0−MT
M0
(2.2)
with M0 and MT the images acquired without and with MT pulse, respectively. MT images
were registered to images without MT pulse. Before any processing, image quality was assessed
for each modality by visual inspection. Table 2.1 lists all sequences properties of the protocol,
and the Figure 2.1 provides an example of all images and maps in one HC and one MS subject.
Total scan time was approximatively 1h08 mins.
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Sequence Parameters Time
T2* (MT)
TR/TE = 47/1.23 ms; 32 echoes, δTE = 1.23 ms; Voxel size =
1.6×1.6×1.6 mm3 ; FoV=136×136×112
11’ 16”
T2
TR = 5000 ms, 21 echoes with δTE = 9 ms; Voxel size =
1.1×1.1×4.0 mm3, FoV=160×192×30
3’15”
MP2RAGE
TR/TE = 5000/2.89, IT1 = 700 ms, IT2=2500 ms; Voxel size=
1.0×1.0×1.2 mm3, FA = 4°;FoV = 256×240×176
8’ 22”
3D FLAIR
TR/TE/TI = 5000/394/1800 ms; Voxel size = 1.0×1.0×1.2 mm3;
FoV = 256×240×176
6’ 27”
3D DIR
TR/TE/TI = 10000/218/3650 ms; Voxel size= 1.1×1.0×1.2 mm3;
FoV = 240×256×160
12’ 52”
MPRAGE
TR/TE = 2300/2.98 ms; Voxel size= 1.0×1.0×1.2 mm3; FoV=
256×240×160
5’12”
Table 2.3: Detailed MS Advanced protocol sequences parameters. Total acquisition time 1h08’.
2.2.4 MRI contrasts
T1 relaxation time (rt) in brain tissue is mainly influenced by free water protons and the degree
of structural organization (i.e. amount of macromolecules such as myelin, lipids, proteins). In
this context, an increase in T1rt may indicate a loss of structure and/or an increase in water
content. Conversely, greater density of macromolecules and reduced water content as well as
iron accumulation tend to reduce T1 [38].
T2-rt measures the loss of spin coherence and therefore, mainly reflect the dynamic state of
water protons and their interaction with macromolecules. An increase in T2-rt characterizes a
loss of macromolecules and/or increased water content. On the contrary, a decrease in T2-rt
reflects an increase of protons bound to macromolecules. As for T1, iron accumulation also
causes a shorter T2 [39].
The effective T2*-rt transverse describe the loss of transverse magnetization due to T2 re-
laxation and magnetic field inhomogeneities (R2’ component [40]). Possible sources are
tissue-dependent differences in magnetic susceptibility or the presence of paramagnetic or
ferromagnetic ions like iron. For these reasons, an increase in T2* most often indicates a loss
of macromolecules, while a decrease suggests an increase of macromolecular compounds or
iron that translate into an increase in R2’.
MT images are based on the interaction between free protons and immobilized protons
bound to macromolecules, so that a lower MTR indicates a reduced spin exchange between
macromolecules and surrounding bulk water suggesting neuroaxonal damage or myelin
breakdown [100] and/or water increase.(see Figure 2.2)
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Figure 2.1: Example of MR images from MS advanced protocol : MP2RAGE uniform image,
MPRAGE, DIR, 3D FLAIR images as well as MP2RAGE T1, T2, T2*, and MTR maps for one
healthy control subject (first two rows) and one MS patient (last two rows). Examples of lesions
are shown by red arrows in the images from the MS patient.
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Figure 2.2: Biophysical basis of MRI contrasts. ++: increase; – : decrease. Big red arrow: large
increase; small red arrow: small increase. Big blue arrow: large decrease; small blue arrow:
small decrease.
2.2.5 Image analysis and tissue segmentation
We used the Elastix c++ library [101] to perform (i) rigid registration with BSpline interpola-
tion of the T2 maps to the T1 maps (from the MP2RAGE); (ii) rigid registration of T2* maps,
MPRAGE, FLAIR, and DIR images to one of the inverted contrasts of the MP2RAGE sequence.
By doing this, we obtained all images in the MP2RAGE space. Regions of interest (ROIs) were
derived from the MPRAGE image using in-house software based on variational expectation-
maximization tissue classification [102]. The following ROIs were automatically segmented:
whole brain WM and cortical GM, thalamus and basal ganglia (caudate, putamen and globus
pallidus), cerebellar WM and GM. In addition, we computed lobar WM and GM (temporal,
occipital, frontal, parietal areas) (see Figure 2.3).
An experienced neurologist (Cristina Granziera, CG) and a radiologist (D. Rotzinger, DR) man-
ually counted MS lesions by consensus in 3D FLAIR, 3D DIR, and MP2RAGE images for all MS
subjects and HC, as performed previously [92]. A trained technician generated manual con-
tours for each lesion in the three different contrasts (re-checked by DR). In order to maximize
the sensitivity of lesion count and volume, lesion masks from each contrast were merged into
a single mask (lesion union mask), as reported in [92] . The lesion union mask and the ROIs
masks were then registered to the T1, T2, T2*, and MTR maps to obtain parametric values in
lesions and NA tissue in each ROI. The volume of each ROI was also automatically obtained
using the in-house software [103] and normalized by total intracranial volume.
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Figure 2.3: Example of tisue segmentation and lobe parcellation using in-house software
MorphoBox. The segmentation was obtained using MPRAGE image as input.
2.2.6 Statistical analysis
Between-groups comparisons of subjects’ demographics and clinical scores
Differences in age, gender, education, and clinical performances were assessed using a non-
parametric ANOVA (Kruskal-Wallis test) among HC and MS patients.
Between-groups comparisons of multi-contrast MRI data
To assess NA tissue differences in mean T1, T2, T2*, and MTR of patients and controls, we
performed a permutation-based Hotelling test with 10.000 permutations, age and gender as
covariates, and family-wise error rate correction for multiple comparisons. The following null
hypotheses were tested:
• (i) there are no differences in WM and GM of temporal, parietal, occipital, and frontal
lobes;
• (ii) there are no differences in cerebellum WM and GM;
• (iii) there are no differences in thalamus and basal ganglia.
Lobar assessment was chosen, instead of whole brain, to take into account the local variation
of quantitative relaxometry measures, as reported previously [104, 105]. In order to determine
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the strength of the significance, we also calculated the Cohen’s d effect size as follow:
d=
x¯1− x¯2
s
(2.3)
with x¯1 and x¯1 are the mean of the group 1 (HC) and group 2 (RRMS), and s defined as follows:
s=
√√√√ (n1−1) · s21 + (n2−1) · s22
n1+n2−2
(2.4)
Parameters s1 and s2 refer to the standard deviation of group 1 (HC) and group 2 (RRMS),
while n1 and n2 are the number of samples of group 1 and 2.
For lesions analysis we normalized T1, T2, T2* and MTR value using z-score :
zT 1 = 1
N
∑
IT 1(ν)−µT 1(Ll ,Tl )σT 1(Ll ,Tl ) (2.5)
where zT 1 corresponds to the T1 lesion z-score (z), l to the lesion voxels, N to a normalisation
term, I the T1 map, µT 1 and σT 1 to the mean and the standard deviation of the T1 map in
the lobe L and tissue T (i.e WM or GM) in the HC group, corresponding to the lesion location.
Averages of each patient’s T1, T2, T2*, and MTR lesion z-scores were also performed in the
whole MS group. This approach was chosen instead of the permutation-based test applied for
NA tissue to account for spatial variation of relaxometry values [104, 105]. A permutation test
was not feasible for each lobe as not all patients exhibited lesions in all lobes.
Between-groups comparison of volumes
To assess volumetric differences in ROIs between patients and controls, we performed a
permutation-based Hotelling test with 10.000 permutations, age and gender as covariates,
and family-wise error rate correction for multiple comparisons.
Linear regression of MRI parameters with clinical scores
A multivariate linear regression of clinical scores was performed using a general linear model
(GLM) applied to:
• T2*, T2, T1, and MTR in the ROIs that significantly differed between patients and HC;
• T1, T2, T2*, and MTR lesion z-scores;
• Cortical/subcortical lesion count and volume.
Age, gender, educational years, anxiety, and depression scores (HAD) were considered as
covariates, since they have been reported to be linked to functional performance [106, 107].
21
Chapter 2. Multi-contrast MRI for normal appearing tissue analysis
Cognitive scores were adapted using the Box-Cox transformation to satisfy the model as-
sumption for normality [108]. EDSS scores were not considered, as they were positive only
in patients.We performed seven regressions, where we used a stepwise regression approach
to select the best prediction model for each dependent variable (clinical scores). Bonferroni
correction was applied for multiple comparisons (seven tests). Cook’s distance (Cd) was
computed to assess the influence of each observation on the regression process, using 4/n
(n: number of observations) as the threshold of significance. Robust regression was used to
reduce influence of the outliers identified by Cook’s distance analysis.
“Leave-one-out” (LOO) cross validation was applied to assess the prediction quality and ro-
bustness of each model. A p-value < 0.05 was considered statistically significant.
All regression analyses were performed using R software (http://www.R-project.org).
2.3 Results
Between-groups comparisons of subject demographics and clinical scores
No significant differences were observed between HC and MS patients in terms of age (p =
0.3) or gender (p = 0.8); however, HC had slightly higher education levels (17 ± 4 years, mean±
standard deviation) than MS patients (15 ± 3 years, p = 0.04). Mean EDSS in patients was 1.6 ±
0.3 (interval: 1-2). The FSMC motor score was significantly higher in MS patients (23.1 ± 10.5)
than in HC (14.8 ± 5.8, p < 0.02). The FSMC cognitive scores, cognitive performance, MSFC
scores, as well as anxiety and depression scores (HAD) were not significantly different between
groups (p > 0.1).
Between-groups comparison of multi-contrast MRI data
In temporal NAWM, mean T2* and T2 were significantly higher in RRMS patients compared
to HC (T2* rt: 55.1 ± 1.55 ms in patients and 53.4 ± 1.35 ms in HC, d = 1.17, p = 0.004; T2
rt: 82.0 ± 2.38 ms in patients and 79.8 ± 2.0 ms in HC, d = 1, p = 0.03) (see Figure 2.4). In
order to assess whether the observed T2* increase in temporal NAWM depended on local
field inhomogeneities, we also compared temporal NAWM R2’ between groups and found no
significant differences. Additionally, parietal NAWM and cerebellar NAWM exhibited a trend
toward higher T2 values in patients compared to HC (parietal NAWM T2: 83.5 ± 2.44 ms in
patients compared to 81.8 ± 2.62 ms in HC; d = 0.7, p = 0.05; and cerebellar WM T2: 85.90 ± 1.69
ms in patients compared to 85.48 ± 1.47 ms in HC; d = 1.62, p = 0.07). Further, no differences
were seen for T1 and MTR in NAWM and cortical NAGM, nor for T2 and T2* in cortical NAGM,
frontal or occipital NAWM.
Finally, no significant differences between groups were found for T1, MTR, T2, or T2* in the
thalamus or basal ganglia.
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Figure 2.4: Histograms and boxplots of T2 and T2* in RRMS patients and HC. (A) (Top): T2*
and T2 mean histograms in NAWM (temporal lobe) for HC (blue) and MS patients (red); (B)
(Below): Boxplots of T2* and T2 in NAWM (temporal lobe) for HC (left) and MS patients (right).
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Results of micro-structural analysis of lesions are reported in Figure 2.5. In the MS cohort, MS
lesions showed a strong increase in T1 mean z-score (4.42) and an important decrease in MTR
mean z-score (-4.09). T2 and T2* z-scores slightly increased (2.33 and 2.25 respectively).
Figure 2.5: Mean z-scores of T1, MTR, T2, and T2* of MS lesions per patient. Each column
represents a patient.
Between-groups comparison of volumes
No significant differences were observed in volumes between MS patients and HC; however,
there was a trend (p = 0.07) toward smaller normalized thalamic volumes in patients (absolute
volume 15.31 ± 1.36 mm3, normalized volume 0.01 ± 0.0006) compared to HC (absolute volume
16.52 ± 2.04 mm3, normalized volume 0.01 ± 0.0003).
Linear regression of MRI parameters with clinical scores
GLM using backward, stepwise regression revealed a highly significant association, confirmed
by cross-validation results, between multi-contrast MRI features and four clinical scores (see
Table 2.4):
• Cortical lesions count and volume, T1, T2, and T2* mean z-score of lesions, T1, T2*, and
MTR mean of temporal NAWM together with gender predicted the SDMT (attention
function) score (adj-R2= 0.6, p = 0.0004).
• T2, T2*, and MTR mean in temporal NAWM in conjunction with T1 and T2 mean z-score
in lesions as well as subcortical lesion volume and educational years, gender and HAD
scores predicted the MSFC (general disability) score (adj-R2= 0.4, p = 0.03).
• T1 and T2 mean in temporal NAWM combined with cortical lesion volume, subcortical
lesion count and HADD score predicted the FSMC cognitive score (adj-R2 = 0.4, p =
0.01).
• T1 and T2 mean in temporal NAWM combined with cortical lesion volume, subcortical
lesion count, and volume with HADD score predicted the FSMC motor score (adj-R2=
0.4, p = 0.01).
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MSFC SDMT
FSMC
Cognitive
FSMC
Motor
Stepwise regression
p-value 0.03178* 0.00051*** 0.01577* 0.01250*
Adj-R2 0.43 0.59 0.36 0.42
Leave-one-out
cross-validation
p-value 0.00080*** 0.00004*** 0.00696** 0.01160*
Adj-R2 0.24 0.44 0.26 0.24
Table 2.4: Regression analysis. Each line corresponds to the corrected p-values, and adjusted-
R2 of each model (n=7) subjected to regression and cross-validation analysis. (*** : p< 0.001),
(** : p< 0.01), (* : p< 0.05).
2.4 Discussion
The present results demonstrate that, combining multiple advanced MRI techniques it is
possible to unravel the nature of subtle tissue alterations in early MS. Moreover, MRI markers of
inflammation and neurodegeneration substantially improved clinical-radiological correlations
compared to conventional measures.
The RRMS patients enrolled in our study exhibited significant increases in T2 and T2* in tem-
poral NAWM, and to a lesser extent in parietal and cerebellar NAWM. These changes hint to
an accumulation of extracellular water (micro-edema) and/or a reduction of macromolecular
content (myelin) in affected brain tissue (see Figure 2.2). In the absence of significant changes
in MTR and T1, which would support the structural explanation, the increase of both T2 and
T2* most likely indicates the presence of subtle edema. Iron loss might also be responsible for
a prolongation of T2 and T2*, but appears to be a less probable cause as no differences were
observed in R2’, which reflects local field inhomogeneities [109]. By combining multiple q/sq
MRI measures, our study confirms work reporting T2 increase in NAWM in early MS [43, 44]
and extends these findings by providing new insights into the pathology underlying those
changes. Our data, however, contradicts studies showing a measured unimodal MTR decrease
in NAWM of early MS patients attributed to myelin loss [110, 111]. These studies focused
mainly on untreated patients and applied magnetization transfer imaging at lower spatial
resolution and lower field strength (1.5 T) than ours. Furthermore, unimodal MTR studies
in MS should be considered with caution, as magnetization transfer imaging alone cannot
discriminate between myelin alterations and variation of water content in tissues [52]. Axonal
degeneration in NAWM of early MS patients was also suggested by unimodal diffusion tensor
imaging (DTI) studies, showing reduced fractional anisotropy (FA) [75, 76]. Nevertheless, this
interpretation may be misleading since a decrease in anisotropy can derive from the loss of
the branched-shape of microglia cells that is typical of their activated-inflammatory form [77].
Thus, another possible explanation is that reduced FA might point to inflammatory rather
than degenerative phenomena. Several studies tried to address the limitation of unimodality
studies by combining T2 relaxometry, MTR measurements [78], and DTI [79]; yet, these studies
focused on selected brain structures (i.e corpus callosum [79] and corticospinal tract [78]) in
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patients with advanced stages of MS [79]. Our approach overcomes the above-mentioned
limits by performing a whole brain analysis of multiple q/sq assessments in early MS.
Our data also showed that both cortical and subcortical lesions were characterized by a strong
increase in T1 and decrease in MTR with relatively modest positive variations of T2 and T2*
(see Figure 2.5). These findings are consistent with previous MRI literature [112, 113] and
histopathological studies [55, 56, 114] showing significant neurodegeneration in MS plaques.
No significant micro-structural alterations were found in NA tissue belonging to the basal
ganglia or thalamus in our MS cohort. Still, volumetric analyses revealed a trend toward lower
regional volumes in patients (p=0.07), which is consistent with thalamic atrophy reported
in larger and more heterogeneous patient groups [115]. Last, we showed that MRI findings
of micro-structural alterations in NA tissue and lesions substantially improved the clinical-
radiological correlation obtained with conventional measures, even in the presence of minor
functional deficits. In fact, a variable combination of relaxometry and MTR values significantly
ameliorated the prediction of cognitive performance (attention), cognitive fatigue, and general
disability obtained with traditional measures of disease burden and patient covariates (see
Table 2.4). Conventional MRI measures of MS disease impact provide only modest correla-
tions with clinical performances, a phenomenon that is known as the clinico-radiological
paradox. Multivariate analyses and multi-contrast, tract-specific measures were proposed to
alleviate this paradox [78, 79], but suffered from the limitations of conventional protocols and
partial brain analyses. Recently, ultra-high field MRI at 7T has been used to identify subtypes
of cortical lesions, whose numbers showed good correlations with disability and cognitive
performance in MS [116]. Extending such work, our multi-contrast approach emerges as a
whole-brain MRI method at a clinically-compatible magnetic field, which produces strong
clinic-radiological correlations for both cognition and disability. Future developments should
aim at reducing the number of sequences required for optimal lesion detection (i.e. MP2RAGE
and 3DFLAIR) as well as at applying accelerated T1-T2* relaxometry sequences to achieve a
well-suited protocol for the clinical workflow.
2.5 Conclusion
In summary, in this chapter we established a methodology combining different q/sqMRI
contrasts to detect subtle pathological changes in brain tissue of MS patients as well as focal
alterations. We observed indeed micro-edema in NA tissue characterized by an increased
of T2 and T2* in temporal NAWM, as well as prevalent tissue degeneration in MS lesions
revealed by a strong increase in T1 and decrease in MTR. Last, we improved correlations
between MRI data and measures of cognition and disability in early and minimally-impaired
MS patients. Additional studies extending the current methods to patients at later disease
stages and containing larger cohorts will be necessary in the future.
In the next chapter, we focused on the MS lesions by extendeding our multi-contrast approach
to model the heterogeneity of tissue damage in MS lesions through a classification framework.
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3 Multi-contrast MRI quantification of
focal inflammation and degeneration
in multiple sclerosis
Abstract
Local microstructural pathology in multiple sclerosis patients might influence their clinical
performance. This study applied multi-contrast MRI to quantify inflammation and neurode-
generation in MS lesions. We explored the impact of MRI-based lesion pathology in cognition
and disability. Relapsing-remitting MS subjects and healthy controls underwent neurological,
cognitive, behavioural examinations and 3T MRI including: (i) advanced MR techniques for
lesion count; and (ii) T1, T2, T2* relaxometry and magnetisation transfer imaging for lesion
tissue characterization. Lesions were classified according to the extent of inflammation/neu-
rodegeneration. A generalized linear model assessed the contribution of lesion groups to
clinical performances. Four lesions classes were identified and characterized by (1) absence of
significant alterations, (2) prevalent inflammation, (3) concomitant inflammation and micro-
degeneration and (4) prevalent tissue loss. Classes (1), (3), (4) strongly correlated with general
disability (Adj-R2 = 0.6, p = 0.0005), executive function (Adj-R2 = 0.5, p = 0.004), verbal memory
(Adj-R2= 0.4, p = 0.02) and attention (Adj-R2 = 0.5, p = 0.002). To conclude, multi-contrast
MRI provides a new approach to infer in vivo histopathology of MS plaques. Our results also
support evidence that neurodegeneration is the major determinant of patients disability and
cognitive dysfunction.
The content of this chapter has been published in [117].
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multiple sclerosis
3.1 Introduction
The hallmark of MS is the presence of multi-focal lesions or "plaques", which are charac-
terized by variable inflammatory, degenerative and reparative processes [118, 119]. Plaques
inflammation is widespread in the relapsing-remitting MS subtype, whereas important tissue
loss is pronounced in progressive MS and in long-standing disease [120, 121]. In addition, new
lesions are mostly characterized by inflammatory phenomena, leading to blood-brain barrier
disruption, while older lesions show a higher proportion of neuro-degeneration and/or repair
processes [24, 121].
Conventional magnetic resonance imaging is a valuable tool to provide information about the
number, location and inflammatory “activity” of focal lesions. Nevertheless cMRI offers only
limited sensitivity to focal pathology in the cortex and little insight into the nature of local
damage. Non-conventional MRI techniques such as Double Inversion Recovery (DIR, Geurts
Radiology 2005) and magnetization-prepared 2 rapid gradient echo (MP2RAGE, Marques
Neuroimage 2010 and Kober 2012) have proven higher sensitivity to focal cortical pathology
than cMRI. Similarly, the combination of multiple cMRI contrasts improved cortical lesions
detection at all field strengths (1.5 T [122], 3T [123] and 7T [124]). Besides, other advanced
MRI techniques have shown to be sensitive to tissue pathology in lesions, such as axonal and
myelin damage (diffusion tensor imaging-DTI and magnetisation transfer imaging-MTI) and
axonal metabolic deficits (magnetic resonance spectroscopy) [119, 125–128]. MRI relaxometry
has also been extensively used to study normal-appearing brain tissue in multiple sclerosis
patients (for review see [128, 129]), but only few works focused on lesions properties and
heterogeneity [95, 130]. Yet, some recent post-mortem studies provided strong evidence of the
value of MRI relaxometry techniques to study specific aspects of plaques pathology; Bagnato
et al. showed that high R2* values in the periphery of white matter (WM) lesions correlated
with iron accumulation in macrophages/microglia whereas high R2* inside the WM plaque
had the appearance of iron aggregates typical of microbleeds [131]. Furthermore, Tardif et
al. established that myelin loss within cortical lesions was associated with a concomitant
increase of T1 and T2 relaxation times and a decrease of MTI measures [55].
In this chapter, we combined three relaxometry techniques (T1, T2 and T2*) and MTI (i) to
classify MS cortical and WM lesions according to the extent of inflammatory and neurodegen-
erative phenomena, as measured by unconventional MRI and (ii) to assess the clinical impact
of MRI measures of lesion pathology in a cohort of relapsing-remitting multiple sclerosis
patients.
3.2 Method
3.2.1 Lesion segmentation
Cortical and WM MS lesions were manually identified in patients by an experienced neurolo-
gist (CG) and a radiologist (DR) using 3D FLAIR, 3D DIR and MP2RAGE images, as previously
reported [85, 91]. Manual contours were generated for each lesion by a trained technician
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for each contrast. As reported by [95] we merged the lesions extracted from FLAIR, DIR and
MP2RAGE to obtain a final union lesion mask for each subject. Lesion volumes were computed
and normalized by total intracranial volume using our in-house software [103]. Only lesions
with more than 10 voxels size were included in the analysis. Lesion masks were then registered
to MP2RAGE space using the registration parameters described in the previous chapter and
mean T1, T2, T2* and MTR were calculated for each lesion.
In order to assess the mean distribution of T1, T2, T2* rt and MTR in HC brain tissue, we seg-
mented lobar WM and cortical GM (frontal, parietal, occipital, temporal) as well as cerebellar
WM/GM from the MPRAGE images. To compare lesion MRI properties in patients with the
corresponding tissue in HC, we calculated a z-score for each contrast in each lesion (e.g. for
T1 data):
zT 1 = 1
N
∑
IT 1(ν)−µT 1(Ll ,Tl )σT 1(Ll ,Tl ) (3.1)
where zT 1 corresponds to the T1 lesion z-score (z), l to the lesion voxels, N to a normalisation
term, I the T1 map, µT 1 and σT 1 to the mean and the standard deviation of the T1 map in the
lobe L and tissue T (i.e WM or GM) in the HC group, corresponding to the lesion location and
type.
This normalisation step provide for each contrast a normalized value corresponding to the
number of standard deviation measured between a lesion voxel and the corresponding healthy
distribution. In this context, a negative value corresponds to a decrease of the quantitative
parameter, while a positive value reflects an increase of the parameter (Figure 3.1).
3.2.2 Lesion classification
Considering the continuous distribution (without distinct cluster) of lesions z-scores in each
contrast (see Appendix A.1), we classified the lesions z-score into 3 groups as follows: (i) z
very low (z < -2), (ii) z very high (z > 2) and (iii) z close to the HC distribution (-2 ≤ z ≤ 2). The
thresholds were chosen considering the fact that more than 95 percent of the z-scores belong
in the interval [-2, 2] in a normal distribution and that values beyond this interval reflect
significant differences in patients compared to controls (p< 0.05). (Figure 3.2). Last, for each
subject, all existing combinations of z were computed for all contrasts (e.g. : combination 1 =
zT 1 > 2, zT 2 > 2, zT 2∗ > 2, zMT R < -2; combination 2 = zT 1 > 2, zT 2 > 2, -2 < zT 2∗ < 2, zMT R < -2,
etc...) and mean lesion volume (MLV) was assessed for each combination (total normalized
lesion volume/number of lesions).
Finally we grouped the combinations in 4 lesion types : Class 1 (Combination 1), Class 2
(Combinations 2-4), Class 3 (Combinations 5-8), Class 4 (Combinations 9-12).
29
Chapter 3. Multi-contrast MRI quantification of focal inflammation and degeneration in
multiple sclerosis
Figure 3.1: Pipeline for MS lesions classification using multi-contrast approach. Computation
of lesion fingerprint using z-score measurement.
3.2.3 Statistical analysis
Regression analysis
Differences in age, gender, education, and clinical performance were assessed using a non-
parametric ANOVA (Kruskal-Wallis test) among HC and MS patients. A multivariate linear
regression of clinical scores was performed using a general linear model (GLM) applied to MLV
in each combinations of contrasts. Age, gender, educational years, anxiety, and depression
scores (HAD) were considered as covariates. Cognitive scores were adapted using Box-Cox
transformation to satisfy the model assumption for normality [132].
We performed seven regressions and applied a stepwise approach to select the best prediction
model for each dependent variable (clinical scores). Bonferroni correction was applied for
multiple comparisons (seven tests). “Leave-one-out” (LOO) cross validation was applied to
assess the prediction quality and robustness of each model. A p-value < 0.05 was considered
statistically significant.
All regression analyses were performed using R software (http://www.R-project.org).
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Figure 3.2: List of the 12 combinations of MS lesions z-scores for T1, T2, T2* and MTR q/sq
MRI from the least (combination 1) to the most (combination 12) severe stage. The presence
of irreversible tissue loss was considered a sign of higher severity than inflammation.
3.3 Results
Contrasts combinations and lesion combination distribution
We found 12 z-scores combinations in all MS lesions (1402 lesions, Figure 3.2). These combi-
nations characterised plaques with no significant contrast changes (Class 1: combination 1,
54% cortical and 46% WM lesions), prevalent inflammatory edema (Class 2: isolated increase
of T2 and/or T2* z-scores, combinations 2-4, 40% of cortical and 60% of WM lesions), micro-
degeneration and/or inflammatory edema (Class 3: increase in T1 and/or increase in T2/T2*,
combinations 5-8, 2% cortical and 98% WM) and broad tissue loss (Class 4: strong increase
in T1 and decrease in MTR z-scores, with or without increase in T2/T2*, combinations 9-12,
100% WM).
Most of the lesions (70%) showed a significantly high T1 z-score (Class 3 and 4) and only 27%
of total number of lesions did not show any significant change in all contrasts (Class 1); 48% of
lesions showed high T1 z-score only (Class 3), 32% exhibited high T1 z-score combined with
high T2 or T2* (Class 3) and 18% were characterized by high T1 z-score combined with low
MTR (Class 4). Class 2 containing lesions with high T2 and/or T2* and "non significant" T1
and MTR counted less than 3% of the total number of lesions (Figure 3.3).
The cortical lesions represented 17% of the total number of lesions; 90% were cortical lesions
Type I (mixed GM/WM) and 10% Type II (GM only). They mainly belong to combination 1
(85%) and combinations 2 to 8. Most of the lesions were pure WM lesions (83%) and appeared
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in all combinations.
Figure 3.3: Distribution of lesions among combinations and distribution of combination
among patients. Combinations 1 (non significant z-score in all contrasts) and 4 (isolated high
T1 z-score) count more than 50% of all lesions and are the combinations mostly found in all
patients.
Linear regression
GLM using stepwise regression revealed a highly significant association, confirmed by a cross-
validation test, between lesions MRI characteristics and three clinical scores (Table 3.1):
• The MLV in combinations 8 and 9 (Class 3 and 4) together with age and depression score
predicted the MSFC (general disability) score (Adj-R2 = 0.6, p = 0.0005).
• The MLV in combinations 5, 6 and 9 (Class 3 and 4) in conjunction with gender predicted
the FV (execution) score (Adj-R2= 0.5, p = 0.002).
• The MLV in combinations 1, 9 and 10 (Class 1and 4) predicted the SRT (verbal memory)
score (Adj-R2 = 0.4, p = 0.002).
• MLV in combinations 1, 5, 6 and 9 (Class 1, 3 and 4) with age and depression score
predicted the SDMT (attention function) score (Adj-R2 = 0.5, p = 0.004). Nevertheless,
cross-validation test revealed a possible over-fitting of the GLM (estimated score vs
clinical score: Adj-R2 = 0.1, p = 0.09)
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MSFC FV SRT SDMT
Stepwise regression
p-value 0.00045*** 0.00166** 0.01536* 0.00379**
Adj-R2 0.55050 0.45350 0.38040 0.48960
Leave-one-out
cross-validation
p-value 0.00005*** 0.00030*** 0.00677** 0.09011
Adj-R2 0.43660 0.37490 0.25620 0.14360
Table 3.1: Regression analysis of clinical scores using lesions characteristics. Each line corre-
sponds to the corrected p-values, and adjusted-R2 of each model (n=7) subjected to regression
and cross-validation analysis. (*** : p< 0.001), (** : p< 0.01), (* : p< 0.05).
3.4 Discussion
Current diagnostic and prognostic criteria in MS as well as clinical trials end-points are based
on conventional MRI measures of lesions number, volume and activity [133]. Nevertheless,
these parameters provide only limited information about the nature and severity of tissue
alterations in the central nervous system. In fact, changes in conventional T1 and T2 signals
are compatible with both inflammatory and degenerative phenomena [80]; moreover, the pres-
ence of "black holes”, considered to be a marker of permanent axonal/myelin loss [134, 135]
might be also due to inflammatory extracellular [135] edema and activated microglia [136,137].
Furthermore, gadolinium (Gd) enhancement, a conventional marker of active inflammation,
does not detect active lesions with mild changes in blood-brain barrier (BBB) permeabil-
ity [138] and disseminated inflammation due to activated microglia [139]. In addition, the
presence of Gd uptake might reveal incomplete restoration of tight junction integrity and BBB
function in inactive, non-inflamed, chronic lesions [2].
We previously showed the potential of advanced MRI techniques allow to unravel the nature of
diffuse and focal tissue pathology in MS (Chapter 2). In this chapter, we aimed at investigating
the influence of unconventional MRI metrics of lesion pathology on patients disability and
cognition. In accordance with previous literature at 3T [95] we found that the majority of
lesions detected in our cohort of early MS patients were located in WM (83%), a moderate
number were mixed WM/GM (Cortical Lesion Type-I) (15%) and few were purely cortical
and punctiform (cortical lesion Type-II) (2%). We identified twelve combinations of MRI
contrasts in MS lesions, which we organized in four main groups according to the predominant
underlying pathology (Figure 3.2). Class 1 was constituted by lesions that did not show any
significant contrast change, possibly due to pathophysiological causes (i.e. presence of more
efficient reparative processes in early stages of disease) and/or technical aspects (lack of
sensitivity/spatial resolution). The other three groups were constituted by lesions exhibiting
prevalent inflammation (Class 2), micro-degeneration with/without inflammation (Class 3) or
predominant tissue loss (Class 4). These four groups were consistent with those reported by the
histopathological “Vienna classification” of MS lesions (Class 1: Vienna lesion type-VLT 6; Class
2: VLT 2; Class 3: VLT 2/5; Class 4: VLT 5) [140]. Interestingly, we did not observe any T1/T2/T2*
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decrease in local plaques, suggesting that no significant iron accumulation occurs in our
cohort of patients. However, since we performed an average lesion analysis, this observation
does not exclude the presence of local iron increase, as previously reported [131, 141].
Last, we studied the relative impact of lesion combinations/groups on clinical performance
in patients. And we found that lesions with concomitant micro-degeneration/inflammation
or important tissue loss had a greater impact on patients’ disability, executive function and
verbal memory than prevalent inflammatory lesions. This result could be due to the presence
of a minority of lesions in the purely inflammatory group (Class 2), which might be due to
the fact that most of the patients were benefitting of immunomodulatory/immunodepressive
therapy. In addition, lesions with no significant changes in multi-contrast MRI (Class 1) played
an important role in verbal memory and attention. This aspect is coherent with the fact that
the majority of Class 1 lesions were located in the cortical layers; yet, it could be also due to
the fact that a proportion of Class 1 lesions is located in eloquent areas. In order to elucidate
this last point, an ongoing study is aiming at integrating the lesion location information in the
current lesion classification.
3.5 Conclusion
In summary, this chapter provides a new approach to infer histo-pathological information
from MS plaques and supports evidence that MRI measures of lesion pathology are strong
determinants of patients’ clinical performance in our cohort. In addition, we propose a model
based on multi-contrast approach to characterized the heterogeneity of tissue damage in MS
lesions through a classification framework.
The next chapter, which focuses on deep gray matter nuclei analysis, presents an innovative
technique based on partial volume estimation, to disentangle the WM and GM components
in deep gray matter structures, providing additional information on the micro-properties of
the tissue affected by MS pathology
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Abstract
The presence of partial volume in brain regions like the deep grey matter nuclei renders quite
challenging the detection and identification of pathological alterations. In this chapter, we
propose a new single-contrast approach to disentangle gray and white matter (GM, WM) in
the thalamus and the basal ganglia. Using a newly developed PV estimation algorithm (Roche
et al. [142]) we computed tissue concentration in each voxel so as to estimate the intensity
characteristic of each tissue throughout a given region of interest (ROI). The proposed method-
ology has been applied to a cohort of patients with early multiple sclerosis patients to assess
its ability to evaluate the impact of subtle and diffuse inflammatory or neurodegenerative pro-
cesses. Fourty-three relapsing-remitting MS (RRMS) patients and nineteen healthy controls
underwent 3T MRI including: (i) FLAIR, DIR, MPRAGE for lesion count; (ii) and T1 relaxometry
for tissue characterization and concentration maps estimation. We applied a newly developed
partial-volume estimation algorithm to T1 relaxometry maps (Roche et al.), and computed
GM and WM tissue concentrations maps to estimate the intensity characteristic of each tissue
in the thalamus and basal ganglia. Then, we performed a qualitative analysis comparing
estimated concentration maps with histological data, and a quantitative analysis consisting of
a group comparison based on the concentration and T1 intensity characteristic in both WM
and GM.Qualitative analysis provided evidence of the precision and validity of our approach
in the deep grey matter nuclei. Group comparison showed significant increase in the T1
of the GM component of the thalamus (p=0.016) in RRMS patients compared to HC. The
presented methodology enables an in-depth characterization of deep gray matter nuclei tissue
properties. This additional information holds promise to identify the presence and nature of
diffuse pathology in neuroinflammatory and neurodegenerative diseases.
The content of this chapter has been submitted to Human Brain Mapping.
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4.1 Introduction
Magnetic resonance imaging (MRI) provides in vivo information about brain tissue integrity
[83]. MRI signal varies across tissue types because gray matter contains a prevalence of cell
bodies (neurons, glial cells etc....) and iron, while white matter is for the majority constituted
by nerve fibers (myelinated and unmyelinated axons) [143, 144]. Nevertheless, as cell bodies
are common in WM, a certain amount of neuronal fibers is also present in cortical and sub-
cortical gray matter (Histology for pathologists Stacey E. Mills).
In T1 relaxometry images for example, the globus pallidus appears with lower T1 (close to
WM T1) compared with other deep gray matter nuclei (DGMN) due to an abundance of
myelin [145]. On the other hand, the putamen, which is composed by packed myelinated
axons [146], appears with a higher T1 (close to GM T1). The presence of several tissue types
results in an intensity mixing effect known as “partial volume” (PV). In brain regions affected
by important PV effects, the DGMN and the cortex (especially in the cerebellum), the identifi-
cation of the tissue type affected by pathology is challenging and pathological effects might
appear undetectable when tissues alterations have an opposite effect on the MRI signal. In the
recent past, a number of multi-contrast MRI approaches have been proposed to image cortical
myelination and differentiate the cellular component from the one constituted by neuronal
fibers in the brain cortex. Glasser et al. computed the ratio between T1- and T2-weighted MR
images to estimate cortical myelin content [147], while Grydeland combined this ratio with
diffusion MRI information to achieve more accurate results [148]. More recently, Shafee et al.
attempted at improving cortical myelin content estimation by introducing a mixture model of
gray and white matter based on T1- and T2-weighted images. As to deep gray matter (DGM)
structures (thalamus and basal ganglia), there have been few attempts to separate their tissue
components based on advanced MRI techniques like relaxometry and magnetization transfer
imaging or quantitative susceptibility mapping [149].
In this chapter, we present a new single-contrast approach, based on MP2RAGE images, to
disentangle WM from GM signal components in the thalamus and the basal ganglia. Using
a newly developed PV estimation algorithm (Roche et al. [142]) we computed tissue concen-
tration in each voxel so as to estimate the intensity characteristic of each tissue throughout a
given region of interest (ROI). This characteristic intensity stands for the idealized signal of
a voxel composed by pure tissue. Results were evaluated qualitatively by comparing the ob-
tained concentration maps with previously published histological data and with high-spatial
resolution 7T data in healthy subjects. Next, we performed quantitative comparison by assess-
ing differences in T1 quantitative MRI contrasts between a group of multiple sclerosis patients
and of healthy subjects.
4.2 Method
4.2.1 Image processing
Extraction of regions of interest
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We segmented the MPRAGE volumes using MorphoBox [103] in order to extract the following
deep grey matter regions : thalamus, caudate, putamen and pallidum. MorphoBox auto-
matically delineates regions of interest (ROIs) by performing a non-rigid registration with a
template, manually defined by 3 neurologists and radiologist by consent.
Concentration map and tissue intensities
The intensity of a voxel in a MR image depends on the pulse sequence used and the type of
molecules present in the voxel volume. In a T1 relaxometry map, this intensity is driven by the
density and type of molecules that compose the tissue. The microstructures in the DGMN can
be neurons nuclei or glial cells, mainly found in the GM, as well as axons and myelin, the main
components of WM [144]. Our approach consists in grouping DGMN cells in two pools, the
GM component and the WM component, and estimate their respective contributions to the
T1 intensity. For each subject, we applied the PV estimation algorithm developed by Roche A.
et al. [142] to the T1 relaxometry map in the extracted ROIs. This algorithm uses a PV model
that describes a voxel intensity as the sum of the GM and WM pooled intensities weighted by
their respective concentrations, up to Gaussian noise :
yi =µGMCGM +µW MCW M +εi with εi = N(0, σ) (4.1)
where yi is the intensity of a voxel i, CGM and CW M are the associated concentrations of GM
and WM, µGM and µWM the characteristic tissue intensities, i.e. the intensities corresponding
to 100% of GM and WM, respectively; εi represents the noise and σ its standard deviation,
which is also estimated by the PV algorithm. After we initialized the vector µ by standard T1
values [85] at 3T for GM (µGM = 1350 ms) and WM (µW M = 850 ms), the algorithm iteratively
estimated voxelwise gray and white matter concentrations and intensities within each ROI.
Since the algorithm can adapt to global intensity changes, the regionally pooled GM and WM
intensity estimates reflect putative T1 signal alterations due to pathology.
4.2.2 Qualitative assessment
In a first place, we qualitatively compared our results with a renowned method computing con-
centration maps. Images were segmented into GM, WM and CSF using SPM8 (Welcome Trust
Centre for Neuroimaging, Institute of Neurology, UCL, London, UK — http://www.fil.ion.ucl.ac.uk/spm),
(see Figure 4.1). Then, we qualitatively compared estimated GM concentration maps with
histological images reported in [150, 151]. In this work, Sadikot and Chakravarty used Nissl
staining to highlight the cells bodies representing GM in red, and blue Luxol to show myelin
of axons of the WM in blue (see Figure 4.3). Their images show variable concentrations of
neuronal cells and myelin in the different structures of the deep gray matter. We used 3T and
7T dataset to estimates our PV maps in order to appreciate the subtle tissue concentration gra-
dient in the different ROIs. We used whole brain estimated concentration maps to ease visual
inspection of the data. In practice global tissue concentration maps turned out qualitatively
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similar to their ROI-based counterparts.
Figure 4.1: Comparison between 2 axial slices of GM concentration maps (first row) and
Statistical Parametric Mapping (SPM) GM probabilistic maps (second row) at 3T. The SPM
map mainly shows binary concentrations, and some parts (pointed out by red arrows) of the
thalamus and putamen disappear compared with concentration maps.
4.2.3 Quantitative assessment
We performed a group analysis to compare RRMS patients and controls for each ROI. We
computed the T1 averaged across each ROI in RRMS patients and controls, and applied a
two-tailed permutation-based two sample t-tests with age and gender as covariates. Then
we performed the same analysis on ROIs revealing significative differences between the two
groups, based on the estimated pooled T1 intensity in GM and WM. as well as the logarithm of
the ratio between GM and WM concentration. A family-wise error rate correction was used
for multiple comparisons correction. Both concentration and intensity tests were corrected
simultaneously.
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4.3 Results
4.3.1 Qualitative assessment
The observation of GM concentration maps using SPM showed similarities with our PV esti-
mated maps. Nevertheless, the SPM maps appeared mostly binary than our PVE maps and
did not represent parts of the thalamus as well as a large part of the putamen (red arrows) (see
Figure 4.1). These results reflect the additional information provided by our method compared
with SPM in deep gray matter regions. Then, we qualitatively compared the results from the
concentration maps obtained from 3T data of 3 healthy subjects with two histological slices
obtained from Sadikot and Chakravarty [150, 151]. The first slice shows the histology of the
thalamus, the caudate and the putamen (see Figure 4.2): neurons nuclei in red, and myelin in
blue. While the concentration of nuclei in the putamen and caudate appears homogeneous,
the thalamus shows a variable amount of cells nuclei which gradually increase towards the
ventricles. The concentration maps estimated from the T1 map at 3T show very similar homo-
geneity in the GM concentration of the caudate (delineated in green) and putamen (delineated
in yellow), while the thalamus (delineated in blue) exhibits an increase of GM concentration
going from the border of the structure to its center. The red coloration in the histological slice
shows a higher concentration of neurons nuclei in the caudate than in the putamen. The GM
concentration map reflects this difference as the caudate appears brighter than the putamen
for the 3 subjects. We also noticed the difference in GM concentrations between the thalamus
and caudate, reflecting the presence of myelin, as shown in the histological data. Furthermore,
the concentration maps visualized the red nucleus (Ru) and the locus niger (Ni),as reported by
histological data.
Figure 4.2: GM concentration map using T1 maps of 3 healthy subjects at 3T and histological
slice with an outline of nuclei of the thalamus on a coronal Myelin-Nissl-stained section
(right).
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Similar observations are made in others coronal slices from estimated concentration maps of
3 healthy subjects scanned at 7T MRI compared with histological stainings [151] (see Figure
4.3). Owing to the higher spatial resolution than 3T data, 7T images showed additional detail:
a GM bridge between the caudate and putamen which is clearly observable on stained images.
The qualitative assessment showed multiple similarities in terms of nuclei structures and
relative concentration of each DGMN between histological data and concentration maps.
Figure 4.3: Comparison between GM concentration map of 3 healthy subjects at 7T and an
histological slice from a healthy human subject . The concentration map were estimated using
the whole-brain T1 map. In the zoomed area of GM concentration map we can observe the
gray matter bridge present in the histological slice between the caudate and the putamen.
4.3.2 Quantitative group comparison using global ROI averaging, T1 tissue inten-
sities and concentrations
The multivariate analysis of T1 pooled intensities and concentration ratios revealed a sig-
nificant difference in the thalamus of RRMS patients (p=0.0016). The analysis of the tissue
T1 intensities and concentrations showed a significant increase of 3% of the GM T1 in the
RRMS patients (Controls: µGM = 1389 ± 47 ms; Patients: µGM = 1427 ± 40 ms; p = 0.016), while
the WM T1 (0.6%) and the concentration ratio (-1%) were not found significantly different
(Controls: µWM = 912 ± 18 ms, µratio = 0.62 ± 0.08; Patients: µWM = 918 ± 14 ms, µratio = 0.61
± 0.07) (see Figure 4.4).
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Figure 4.4: Boxplots of the WM and GM of the thalamus for RRMS patients and controls using
the proposed PV method. It shows significant increase in the T1 of the GM components
between the RRMS patients and HC.
Figure 4.5: Boxplots of the WM and GM of the putamen for RRMS patients and controls
using PV method. This method showed no significant increase in the T1 of the GM and WM
components neither concentration ratio between the RRMS patients and HC.
The putamen, caudate and pallidum did not show any significant changes between RRMS
patients and HC using the multivariate analysis (see Figure 4.5). The global averaging analysis
showed significant differences in the thalamus but also in the putamen between RRMS patients
and HC. In both structures, we observed a significant T1 increase in RRMS patients compared
with HC (thalamus: p = 0.038; HC : µT1 = 1094 ± 33 ms; RRMS : µT1 = 1110 ± 22 ms ; putamen:
p = 0.026; HC : µT1 = 1136 ± 35 ms; RRMS : µT1 = 1156 ± 27 ms, see Figure 4.6).
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Figure 4.6: Boxplot of mean T1 in the thalamus and putamen using global averaging method.
This method showed significant increase of T1 in both ROIs in RRMS patients compared with
HC.
4.4 Discussion
This study presents a new approach to disentangle GM and WM in regions affected by PV
like the thalamus and the basal ganglia. The proposed methodology provides quantitative
estimations of GM and WM voxelwise concentrations and pooled intensity values that are
characteristic of GM and WM within a particular region, opening new perspectives to evaluate
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the impact and the nature of pathological processes in these brain regions.
The comparison with concentration maps estimated using a publically available software
(SPM8) revealed similarities and some differences. Specifically, SPM maps had an overall
comparable global appearance with the one obtained with our method, though our maps
visualize parts of the thalamus and putamen, which were not visible on SPM maps. In parallel,
the qualitative comparison of estimated tissue concentration maps with histological data
showed remarkable similarities. The heterogeneity of cells nuclei concentration in the thala-
mus, as well as the variable amount of myelin among the DGMN, could indeed be observed
in GM concentration maps as shown in the histological slices. Also, the concentration maps
estimated from 7T MRI data showed subtle structure such a GM bridge between the caudate
nucleus and the putamen in addition to the detailed microstructure already revealed by 3T
maps. All together therefore, these findings provide qualitative validation of the PV estimation
technique, recently proposed by of Roche et al. [142].
Furthermore, group analysis showed a significant changes between MS patients and controls
in the thalamus (p=0.038) and putamen (p=0.026). The changes in the thalamus were mainly
reflected by an increase of the intrinsic T1 value of the GM in RRMS patients (p=0.016), with
no significant changes in the T1 of the WM component nor in the concentration ratio. At
the same time, the analysis of the putamen did not show significant changes in the T1 of the
GM and WM nor concentration ratio, but revealed an increase in the 3 components. These
results suggest that the pathology in the thalamus seems to mainly affect the microstructure
elements composing the GM pool, while in the putamen the WM and GM pools appeared less
but equally affected.
From a patho-physiological viewpoint, these findings imply the presence of a diffuse alter-
ation of the tissue in the thalamus and putamen, which may be due to a loss of tissue or an
increase in water component. This might reflect a stage preceding atrophy, which has been
already reported in the thalamus since the early stages of the MS [152]. Our approach provided
additional information and improved our understanding of the underlying processes involved
in brain tissue alteration in ROIs affected by PV. Although global averaging method remains
sensitive to compare MR intensities in ROIs, our method may also reveal changes in DGMN in
a more sensitive way. In fact, a multivariate analysis (e.g. MANOVA) may be more appropriate
in case of larger cohort, to detect subtle changes.
Yet, our approach suffers from some limitations. Concerning the intensity model we used, it
considers that the characteristic intensity of a tissue is homogeneous over the whole region of
interest. This hypothesis is questionable for large regions of interest such as the cortical gray
matter, and may limit the validity of our method to small regions such as the DGMN. Moreover,
the estimation of the PV becomes ambiguous when the tissue is so alterated that its intensity
is drastically changed. Consequently, focal alterations such as lesions, could be confused with
voxels with high GM concentration in T1 maps for example. Therefore, an exclusion of the
lesions should be considered before estimating concentration maps.
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4.5 Conclusion
In summary, our study proposed a single-contrast approach which provides novel and relevant
characteristics of brain tissue in regions affected by partial voluming. In this context, the
analysis of basal nuclei and thalamus which are involved in the physiopathology of various
neurodegenerative diseases [153], may be improved and lead to new perspectives to under-
stand underlying processes of the pathology. Additional studies extending the PV approach to
other regions (lobes, cerebellum) and other qMRI would provide whole-brain concentration
map, and allow to compute spatial comparison map between individual and control group
(see Conclusion : Perspectives).
In the next chapter we present the results of a longitudinal analysis based on our q/sq multi-
contrast approach, and we show the potential of our methodology to monitor disease over 2
years.
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contrast advanced MRI
Abstract
Clinical monitoring of RRMS patients evolution and therapy efficacy plays a key role in MS
since a number of treatments have been shown to substantially reduce the number of clinical
relapses and disability, as well as the extent of local inflammation and brain volume loss [154].
Recently, a number of non-conventional MRI techniques have been applied to disease follow-
up, to overcome the limitations of conventional MRI due to their low sensitivity to diffuse and
subtle changes in brain tissue. In this chapter, we used longitudinal MRI data acquired over 2
years to assess (i) the sensitivity of multi-contrast MRI (mcMRI) to longitudinal changes in
normal appearing brain tissue and lesions, and (ii) the prognostic value of baseline mcMRI
metrics to predict motor and cognitive performance at 2 years in MS patients. Results showed
significant changes in normal brain tissue due to aging effect characterized by an increase of
T1 and a decrease of MTR in MS patient and controls. Lesions analysis revealed significant
changes suggesting reparative processes such as remyelination and scar formation. Finally
the combination of quantitative MR measurements of focal and diffuse pathology from the
first time-point showed strong correlation with clinical score of the second time-point.
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5.1 Introduction
To date, there is no cure for RRMS but a number of treatments have been shown to substantially
reduce the number of clinical relapses and disability, as well as the extent of local inflammation
and brain volume loss [154]. Clinical monitoring of RRMS patients evolution and therapy
efficacy relies on neurological and disability assessment, which is often insensitive to mild
and subclinical disease progression. On the other hand, conventional magnetic resonance
imaging (MRI), such as T2-weighted and gadolinium enhanced MRI, provide quantitative
measurements of local MS pathology (lesion number and volume) as well as on inflammatory
activity [155]. In addition, conventional T1-weighted MRI is sensitive to the presence of severe
local tissue loss ("black holes") [155], and provides the basis for volumetric estimations and
brain atrophy assessment [28, 156]. Yet, conventional MRI has low sensitivity to diffuse and
subtle brain alterations, and provides with metrics that only partially correlate with patients
function and disability [157–159]).
In this context, a number of non-conventional MRI techniques have been applied to overcome
the limitations of conventional MRI, such as Magnetisation Transfer Imaging, Diffusion Ten-
sor Imaging, relaxometry and spectroscopy [160]. Nevertheless, single contrast approaches
provides only limited knowledge about the nature of measured alteration. We recently showed
that advanced multicontrast MRI (mcMRI) provides metrics to quantify the extent and the
nature of focal and diffuse pathology in MS, with higher specificity than single contrast ap-
proaches; besides, we determined that metrics of tissue mictrostructural integrity as obtained
with cMRI improved the clinico-radiological correlations obtained with conventional mea-
sures only (lesion number and volume).
In this chapter, we assessed (i) the sensitivity of mcMRI to assess longitudinal changes in brain
tissue properties of a cohort of MS patients compared to healthy controls, that we followed-up
for 2 years; and (ii) the prognostic value of baseline mcMRI metrics to predict motor and
cognitive performance at 2 years in MS patients.
5.2 Methods
Thirty RRMS patients out of 36 and 9 HC out of 20 were enrolled for a second scan session 24
months after the first scan. Seven patients and one control were discarded because one or
more datasets were artefactual.
The cohort of interest consisted therefore of 23 RRMS patients (17 women / 6 men, age = 35.7
± 11.8 years) and 8 HC (2 women / 6 men, age = 34.3 ± 9.2 years). The MRI protocol was the
same for the 2 time-points as well as the cognitive, behavioural and motor tests applied (see
Chapter 2.2.3).
As to therapy, thirty patients (83%) were under immunomodulatory treatment (high dosage
IFN beta or fingolimod) for at least 3 months. No patient had received corticosteroid therapy
within the three months preceding the enrollment.
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5.2.1 Tissue and lesions segmentation and images registration
Morphobox [103] was used to segment tissues and structures (lobes, deep gray mater nuclei
etc...) on MPRAGE images for both time-points. Images were registered to the MP2RAGE
space using the same approach presented in Chapter 2.
Lesions were manually segmented on 3D FLAIR, DIR and MP2RAGE images also for the second
time-point by an expert technician, who reviewed also the first time-point for consistency.
The lesions masks of the second time-point were all registered with lesions masks of the first
time-point (TP1) so we could match the same lesions identification number.
5.2.2 Image processing and lesions classification
For both time-points, we extracted mean T1, T2, T2* and MTR in the gray and white matter
components of the following ROIs: frontal lobe, temporal lobe, parietal lobe, occipital lobe,
cerebellum, thalamus and basal ganglia. Normal appearing tissue was obtained in each ROI
by subtracting the lesions union mask.
The lesions were processed separately using the methodology presented in chapter 3. We com-
puted T1, T2 and MTR z-scores for all lesions and we assigned each lesions to its corresponding
combination and group (see Chapter 3.2.2).
5.2.3 Statistical analysis
Normal appearing tissue and volumetry
MANOVA was used to study the influence of a number of independent variables (age, gender,
patients group, MRI sequence and time-points) on the four dependent variables represented
by T1, T2, T2* and MTR mean in each brain ROI (WM, GM, cerebellum, thalamus and basal
ganglia).
Based on the MANOVA results, we then performed a number of ANOVA tests to assess the
influence of the time-points and of the group, on each MRI sequence (T1, T2 and MTR).
Time-point 1 vs. Time-point 2
In order to analyse the changes over 2 years, we performed paired t-tests for each contrast and
group. This analysis considered multiple pairs of observations (mean of the corresponding
contrast and region) to assess the following H0 hypotheses:
• There are no differences in the mean T1, T2 and MTR of the GM and WM of the temporal,
frontal, parietal and occipital lobes between TP1 and TP2.
• There are no differences in the mean of the T1, T2 and MTR of the GM and WM of the
cerebellum between TP1 and TP2.
• There are no differences in the mean of the T1, T2 and MTR of the thalamus, caudate,
47
Chapter 5. Longitudinal analysis of multi-contrast advanced MRI
putamen and pallidum between TP1 and TP2.
All tests were corrected for multiple comparison using Bonferroni.
Patients vs. Controls Group
In order to differentiate normal aging and pathological effects, we computed the difference
between the time-points in each contrast for all patients and controls, and performed two-
sampled t-tests to assess the following H0 hypotheses:
• There are no differences in the evolution of the T1, T2 and MTR of the GM and WM
of the temporal, frontal, parietal and occipital lobes between the control and patient
group.
• There are no differences in the evolution of the T1, T2 and MTR of the GM and WM of
the cerebellum between the control and patient group.
• There are no differences in the evolution of the T1, T2 and MTR of the thalamus, caudate,
putamen and pallidum between the control and patient group.
All tests were corrected for multiple comparison using Bonferroni.
Volumetry
We performed two-sampled t-tests analysis to measure the difference of normalized volume
of the global GM and WM, as well as the thalamus and basal ganglia between patients and
controls groups. All tests were corrected for multiple comparison using Bonferroni.
Lesions
In order to detect changes in lesions evolution, we measured changes in lesions combinations
and groups. We grouped the 12 combinations in 4 main groups and we performed a paired
two-sampled t-tests in each group. Results were corrected for multiple comparisons using
Bonferroni.
In order to assess the potential of mcMRI to predict the appearance of new lesions or lesions
expansion, we computed the mean T1, T2 and MTR value at TP1 of the region corresponding
to new lesions and expanding lesions at TP2. Then we performed a two-sampled t-test for
each contrast between the mean value of the region defined previously and the mean value
of the healthy tissue in the corresponding lobe. Last, we repeated the analysis by replacing
healthy tissue mean value by the normal appearing tissue characteristic T1, T2, T2* and MTR
at TP1.
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Regression analysis
A multivariate linear regression of clinical scores was performed using a general linear model
(GLM) on TP1 MRI data (regressors) and TP2 clinical scores (predicted variables). Age, gender
and educational years were considered as covariates.
Due to the small cohort of subjects, we considered global measurements and not lobe-wise
mean. We also added T1, T2, T2* and MTR lesion z-scores to assess their prediction potential
in clinical scores. Cognitive scores were adapted using Box-Cox transformation to satisfy
model assumption for normalization. EDSS scores were not considered, as they were positive
only in patients. We performed seven regressions, where we used a stepwise approach to select
the best prediction model for each dependent variable (clinical scores). Bonferroni correction
was applied for multiple comparisons (seven tests).
“Leave-one-out” cross validation (LOOV) was applied to assess the prediction quality and
robustness of each model. This last analysis extracted a correlation coefficient between the
predicted value and the real one. All regression analyses were performed using R software
(http://www.R-project.org).
5.3 Results
5.3.1 Normal appearing tissue and volume analysis
The MANOVA showed that the time-points, the group and the age significantly influenced the
evolution of all contrasts. Therefore we performed ANOVA on time-points and group effect
separately considering age as a covariates.
Time-points effects
In patients normal appearing tissue, we observed a significant increase in the T1 in the WM
of the occipital and lobe frontal lobes (occipital : p = 1.2e-04, frontal : p = 0.012), as well as
in the WM and GM of the temporal lobe (WM : p = 5.86e-05; GM : p = 0.011) between the 2
time-points Figure 1-a. We also measured an increase in T1 in the WM of the cerebellum (p =
0.016) and a significant decrease in the pallidum (p = 0.0089).
We observed a decrease of T2-rt in the WM of the occipital and parietal lobes (occipital : p =
3.2e-07; parietal : p = 3.99e-06), as well as the GM of the frontal lobe (p=0.026) between the 2
time-points. We also measured a decrease in T2-rt in the pallidum and putamen (pallidum : p
= 0.0206; putamen : p = 0.04), and an increase in T2 in the caudate (p = 0.039).
T2* was greatly increased in the frontal and temporal lobes of MS patients vs controls (frontal
: p = 1.37e-04; temporal : p = 3.60e-10), nevertheless we mainly attributed those differences
to strong distortion artefact that we observed in these regions at TP2. In the cerebellum, we
found a significant increase of T2* in WM (p = 0.027) as well as in the caudate (p = 0002) and
the putamen (p = 0.0003). The MTR showed a significant decrease in the GM of the occipital
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lobe (p = 0.003).
Significant changes were also measured in normal appearing tissue of controls with an increase
of the T1 of the temporal WM (p = 0.0002), and a decrease of the T2 of the parietal WM (p =
0.007). We measured significant decrease of the T2 in the putamen of controls (p = 0.0012), as
well as an increase of T2* in the caudate (p = 0.023) and putamen (p = 0.044).
All graphs illustrating changes in T1, T2 , T2* and MTR are in Appendix A.3-A.7.
GM WM
Occipital Frontal Temporal Parietal Occipital Frontal Temporal Cerebellum
T1 n.s n.s 0.011* n.s 0.00012** 0.012* 5.86e-05*** 0.016*
T2 n.s 0.026* n.s 3.99e-06*** 3.2e-07*** 0.007* n.s n.s
T2* n.s n.s n.s n.s n.s n.s n.s 0.027*
MTR 0.003* n.s n.s n.s n.s n.s n.s n.s
Caudate Putamen Pallidum
T1 n.s n.s 0.0089*
T2 0.039* 0.04* 0.0206*
T2* 0.002* 0.0003** n.s
MTR n.s n.s n.s
Table 5.1: Paired two-sampled t-tests p-values for RRMS patients in significant ROIs for all
contrast between TP1 and TP2. n.s : non significant.
WM CN
Parietal Temporal Caudate Putamen
T1 n.s n.s n.s 0.0002**
T2 0.007* n.s n.s 0.0012*
T2* n.s n.s 0.023* 0.044*
Table 5.2: Paired two-sampled t-tests p-values for controls in significant ROIs for all contrast
between TP1 and TP2. n.s : non significant.
Groups effects
We did not find any significant difference between changes observed in RRMS patients and
control group. The volumetric analysis did not show any significant group differences in the
observed changes in T1, T2, T2* relaxation times and MTR between time-points.
5.3.2 Lesions
The paired t-tests on lesions revealed significant decrease of T1-rt and T2-rt and an increase
of MTR (T1 : p = 6.18e-43; T2 : p = 6.54e-04; MTR : p =1.60e-04) Figure A.8. The analysis of the
longitudinal evolutions of lesions combinations and groups showed different effects in the
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four groups. The first group, composed by lesion with no difference in T1, T2, T2* and MTR
with healthy tissue, showed no significant changes between the time-points (p = 0.5). This
group counted for 35% of the total number of lesions at the TP1, and 45% at TP2. Most of the
lesions from this group (88%) remained in the same group, while the rest equally divided in
the Class2 (6%), Class3 (4%) and CLass4 (2%) Figure(5.1).
Figure 5.1: Evolution of lesions among the different group based on qMRI combination.
Also the second group, composed by lesions exhibiting prevalent inflammation, did not show
any significant changes between the two time-points (p = 0.3). This group counted for 6%
of the total number of lesions at TP1 and increase to 20% of the lesions of TP2. 45% of the
lesions of this group remained in the same group, while 47% evolved to the Class1 and the rest
evolved to Class3 (8%) Figure(5.1).
The third group of lesions, including lesions with micro-degeneration with or without in-
flammation showed significant changes (p = 6e-06), characterized by an evolution toward
combinations reflecting milder tissue alterations. This group counted for 50% of the total
number of lesions at TP1 and increased to 53% at TP2. Twenty-three percent of the lesions of
this group evolved to Class1 (23%) and few of them in Class2 (6%) and Class4 (6%), while more
than the half of the lesions (65%) remained in the same group Figure(5.1).
Similarly the Class4, composed by lesion with predominant tissue loss, showed significant
changes between the two time-points (p = 3.06e-09) (Figure 4). This group counted for 8% of
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the total number of lesions at TP1, and decreased to 7% at TP2. Most of the lesions evolved to
Class3 lesions (58%) and few to Class1 lesions (8%), while the rest remained in the same group
(34%) Figure(5.1).
Finally, the analysis of the tissue in TP1 where new lesions will appear on TP2, showed a
significant increase in T1 (p = 1.24e-05) and T2 (p = 1.24e-06) in patients compared with
healthy tissue as well as with normal appearing tissue surrounding the analyzed regions (T1
: p = 0.018; T2 : p = 5e-04). We also observed a significant decrease of MTR compared with
healthy tissue (p = 0.005), but no changes with normal appearing tissue (p = 0.4). Figure A.9.
Likewise, the regions where lesions expanded also showed significant increase of T1 compared
with healthy tissue (p = 1e-56) and with NA tissue (p = 1e-46), as well as an increase of T2
(healthy tissue : p = 2.8e-71; NA : p = 7.7e-54) and T2* (healthy tissue : p = 4.07e-13; NA : p =
1.05e-05), and a decrease of MTR (healthy tissue : p = 7.7e-41; NA : p = 1.07e-36) Figure 5.2,
Figure A.10.
Figure 5.2: Example of new lesions on q/sq MRI contrasts. Though we found significant
difference between normal appearing tissue and HC in regions where lesions will appear (red
square), we can not see any evidence of changes in q/sq MRI before lesions appearance.
5.3.3 Regression analysis
GLM using stepwise regression revealed a highly significant association, confirmed by cross-
validation results, between multi-contrast MRI features and three clinical scores (Table 2):
• T1, T2 mean z-score of lesions and T1, T2, T2*, and MTR mean of NAWM and NAGM
together with age and education predicted the word list generation (memory function)
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score ( Adj-R2: 0.97, p = 0.0001; LOOV : 0.28).
• T1, T2, T2* and MTR mean z-score of lesions and T1, T2, T2*, and MTR mean of NAWM
and NAGM together with age, gender and education predicted the FSMC cognitive
(fatigue) score (Adj-R2: 0.97, p = 0.006; LOOV : 0.61).
• T1 T1, T2, T2* and MTR mean z-score of lesions and T1, T2, T2*, and MTR mean of
NAWM and NAGM together with age, gender and education predicted the FSMC motor
(fatigue) score ( Adj-R2: 0.93, p = 0.01; LOOV : 0.41).
Word list
generation
FSMC
cognitive
FSMC motor
p-value 1.27e-04*** 0.006* 0.0105***
Adj-R2 0.9795 0.9750 0.9391
Leave-one-out 0.28 0.61 0.41
Table 5.3: Regression results using MRI data from Time-point 1 to predict clinical scores from
Time-point 2.
5.4 Discussion
Our longitudinal study shows that multicontrast quantitative and semiquantitative MRI is
sensitive to local and diffuse pathology evolution in a group of RRMS patients under im-
munomodulatory and immunodepressive therapy. In addition, multi-contrast MRI metrics
provided strong predictors of memory function and fatigue at two years follow-up.
In RRMS patients, we observed a small difference between time-points in mean T1, T2, T2*
and MTR in normal appearing tissue. These minor parametric variations (<3%) over two
years follow-up are compatible with changes observed during normal aging processes. In fact,
Callaghan et al. observed similar T1 increases in several regions of the brain (1% to 1.6% over
one year [161]). Likewise, the same authors and several others studies [162–164] reported a
decrease of quantitative MT value between 1.5% and 2.5% in one year, while we measured a
decrease of MTR around 5% in two years.
The changes in T1 are associated with degenerative changes on myelin sheaths due to normal
aging [38, 165]. The decrease of MT ratio in GM may reflect neuronal or nerve fibers loss [166].
We also observed an increase of T2*-rt in the caudate and putamen (<5%) over the two years,
which was accompanied by an increase in T1-rt and T2-rt in the caudate, and a decrease of
T1 and T2 in the putamen. This effect might originate from iron loss due to degenerative
changes in the basal ganglia [161] but since changes in the other parameters were quite
modest (<5%), the interpretation of these findings remain challenging. Future studies in
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larger cohorts, including patients at more advanced disease stages, may help distangling the
pathophysiological mechanisms T2* changes in the basal ganglia.
The analysis of T1, T2 and MTR of lesions showed an improvement revealed by a significant
global decrease of T1-rt and T2-rt, and combined with a global increase of MTR. These results
suggest a repair activity within the lesions. The individual analysis of MS lesions revealed
changes in all lesion groups though only changes in Class3 (lesion with both inflammation
and degeneration) and Class4 (lesions with predominant degeneration) reached significance.
A significant part of Class3 (p=6e-06) and Class4 (p=3.06e-09) lesions evolved to lesions with
milder alterations (Classes 1-3). In Class3, we observed a decrease of T1, T2 and or T2*
reflected by an evolution of the lesions toward Class1 ( 20%) and Class2( 6%). This changes
might indicate an attenuation of inflammatory and degenerative phenomena. Nonetheless,
most of Class3 lesions (65%) remained in the same group suggesting that micro-degeneration
is counterbalanced by remyelination process [118]. Only few lesions from Class3 evolved to
more advanced stage in Class4 (6%) where MTR decrease reveal a destruction of tissue and
may suggest an acute phase of the lesions. In group 4, we observed an increase of MTR in
lesions that evolved to Class3 (58%). These changes suggest a reparative activity characterized
by remyelination and/or scar tissue formation [118, 167]. A third of Class4 lesions remained in
the same group, providing evidence that repair mechanisms did not counter-balanced the
tissue loss.
Although we did not measured significant changes in lesions from Class1 (p=0.5) and Class2
(p=0.3), a minority of Class1 lesions (12%) evolved toward more advanced stages including
inflammatory and degenerative activity. As to Class2, a very small number (8%) showed
evidence of micro-degeneration or tissue loss after 2 years, but almost half of Class2 lesions
even evolved toward milder stage, which may be due to reabsorption of inflammatory oedema
[118]. In summary, therefore, the analysis of lesions evolution revealed different underlying
processes that modified tissue microstructure, and that reflect the balance between injury and
repair capacity of the brain.
Interestingly, the analysis of the normal tissue at TP1 that evolved into lesion tissue at 2
years follow-up showed a significant increase of T1-rt and T2-rt and a decrease of MTR when
compared with healthy tissue in HC and tissue surrounding the lesions in patients. This
suggests an increase in water content of the pre-lesion tissue and/or tissue loss. Filippi
and Pike previously observed MTR abnormalities up to 2 years before lesions appearance,
suggesting primary myelin damage before inflammatory mediated brain-blood barrier dis-
ruption [168, 169]. Fazekas et al. also measured a significant drop of MTR six month before
lesions appearance, combined with an increase of T1 native relaxation time [170]. Though
MTR decrease was interpreted as demyelination, it could actually suggest water accumulation
in the form of micro-oedema, which is what we observed in a previous study [80].
Last, relaxation times and MTR in NA tissue combined with mean lesions z-scores at the first
MRI strongly predict patients cognitive (Adj-R2: 0.97, p = 0.006) and motor fatigue (Adj-R2:
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0.97, p = 0.0001) as well as memory (Adj-R2: 0.97, p = 0.01) at 2 years follow-up. This study
extend results obtained at TP1 (Chapter 2), by showing the longitudinal predictive power of
mcMRI even in patients with mild clinical deficits.
5.5 Conclusion
In conclusion, mcMRI provided sensitive measures to assess longitudinal changes of diffuse
and focal brain tissue abnormalities, over 2 years. We also measured quantitative T1 and T2
abnormalities preceding lesions appearance suggesting presence of micro-edema. Finally,
we provided evidence of the strong prognostic value of baseline mcMRI metrics to predict
motor and cognitive performance at 2 years in MS patients. Future studies should confirm
and extend our findings in other MS disease subtypes and with longer follow-up.
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6 Conclusion : Achievements and Per-
spectives
This thesis aimed at studying the micro-properties of brain tissue in MS patients using new
advanced techniques in MRI. Initially, we established a methodology combining different
q/sqMRI contrasts to detect diffuse subtle pathological changes in brain tissue of MS patients
as well as focal alterations. We also showed how to take advantage of the complementarity of
q/sqMRI sensitivity (i.e. changes in water, macro-molecules, iron...), to identify the physio-
pathological process underlying tissue microstructure alterations in MS. Then, we extended
our multi-contrast approach to model the heterogeneity of tissue damage in MS lesions
through a classification framework. We also presented an innovative technique based on
partial volume estimation, to disentangle the WM and GM components in deep gray matter
structures, providing additional information on the micro-properties of the tissue affected by
MS pathology. Last, we showed the potential of our approach to monitor MS patients over a 2
years period, and particularly to identify repair and degeneration activity in brain tissue.
6.1 Achievements
The results we reported in this thesis may have potential impact both at a methodological and
clinical application level.
On a methodological level, we established that multi-contrast q/sq MRI provides higher
sensitivity and specificity than single contrast approaches.
• We showed the sensitivity of q/sqMRI to subtle changes in large regions as well as in
focal areas and provided metrics to estimate the physiopathology of observed tissue
alterations.
• Based on these metrics, we proposed a new classification method of MS lesions pathol-
ogy and their evolution, which recalls histopathological data in MS patients.
• Last, we revealed the potential of a partial volume approach based on T1 relaxometry
contrast, to detect subtle pathological and tissue-specific effect in the deep gray matter
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nuclei.
In term of clinical applications, the constant development of MR technology and the accel-
eration of MR sequences acquisition might render q/sq MRI clinically compatible in a near
future. Of course, extension to more advanced and bigger MS cohorts as well as reproducibility
studies in a multi-centre settings are required before foreseen the introduction of q/sq MRI in
clinical protocols; however, the current work sets the basis for future investigations.
6.2 Perspectives
In this thesis, we performed a comparison between MS patients and healthy controls groups.
Yet, clinical applications are based on single-patients evaluations. Therefore, we conceived a
pipeline model to perform analysis of tissue microstructure in a single MS patients. Specifically,
we created a voxel-wise deviation map of an individual by computing z-score maps for each
q/sq contrast. We then incorporated the partial volume estimation technique in the pipeline
to identify the WM and GM components in each brain structure.
Figure 6.1: Pipeline for deviation maps computation. The inputs are the q/sq MRI concentra-
tion maps, as well as the normative ranges of WM and GM in each brain structure.
Subsequently, we computed the normative ranges of 3 contrasts (T1, T2, MTR) in all brain
regions (lobes, basal ganglia, cerebellum) for each tissue (GM, WM) in the control population
(n=18). Then, we computed the z-score map of the 3 contrasts from the concentration maps
for each a single patient. Figure 6.1.
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We performed our pipeline on T1, T2 and MTR contrasts. The results show relevant repre-
sentation of diffuse changes, particularly in the T2 relaxation time Figure 6.2. The analysis of
lesions show strong changes in T1, T2 and MTR inside the lesions but also in the surrouding
area. Our maps provide evidence of diffuse alteration of the tissue characterized by T2 and
MTR variations. These results may help to improve our understanding of tissue alterations,
and should help to identify more precisely areas where pathology occurs.
Figure 6.2: Deviation maps of T1, T2 and MTR contrast. In order to adapt the colormap to
theT1 and T2 contrasts, the MTR deviation map shows the opposite of the MTR z-score (zMT R
= -z). The color code shows in dark blue the negative z-scores (decrease of T1, T2 and an
increase of MTR), in light blue a positive z-score, and in yellow to red a high z-score (increase
of T1, T2 and decrease of MTR). Based on this color code, the analysis of the lesions shows
strong changes in T1, T2 and MTR z-scores within the lesions but also in the surrounding area.
This technique which showed promising preliminary results, presents advantages compared
with existing methods such as voxel based morphometry. First of all, this methodology is based
on brain tissue identification (GM, WM, CSF) and comparison with normative ranges which
does not require any inter-subject registration. This technique combined with partial volume
method giving precise tissue concentration information, may also allow a finer analysis of
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challenging areas such cortex and cerebellum. Nevertheless, this approach requires a large
cohort of healthy subjects to correctly set the normative ranges. In addition, lesions masks
are required rendering this approach only feasible when an automatic and reliable lesion
detection tool is available.
In summary, we set up a method that we foresee can be easily applied in the future to provide
a visual map of brain tissue pathology in single MS patients. Future work should focusl in
building up robust normative ranges in the healthy population as well as integrating automatic
lesion assessment algorithms in the current pipeline.
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A.1 Preliminary analysis on lesions classification
In a preliminary analysis of MS lesions, we performed correlation analysis between the z-
score distribution of each contrast (Figure A.1). We also analysed outliers and the association
between distribution of lesions z-score among the 4 q/sqMRI with lesions size, type (GM, WM,
mixed GM/WM), and location (Figure A.2). Finally we performed an automatic classification
of lesions according to their 4 z-scores using a simple K-mean algorithm.
As excepted, we noticed a strong positive correlation between T1 and T2 z-scores, as well as a
negative correlation between T1 and MTR z-scores (Figure A.1). The analysis of the outlier
pointed out segmentation issue in periventricular lesions, where CSF is wrongly include in the
lesions leading to very high z-score. In fact it compared wrong tissue type. The distribution
of lesions z-score did not show any significant association with lesions size, type or location.
Finally, the K-mean algorithm showed no significant results, reflecting absence of cluster in
the data. The distribution of lesions z-scores appear indeed continuous in the 4 contrasts.
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Figure A.1: Distribution of all lesions according to their T1, T2 and MTR z-score. The distri-
bution shows no cluster. The red dashed lines delimit the threshold manually set for lesion
classification.
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Figure A.2: Distribution of lesions z-scores according to their type, size and location. Cortical
lesions appeared to have lower z-score, due to their low contrast. No sign of correlation
between T1, T2, T2* and MTRz-score value and lesions size and location.
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A.2 Longitudinal analysis of RRMS patients and controls
We present here the figures illustrating the changes in T1, T2, T2* and MTR in the regions were
it appeared significant.
Figure A.3: Boxplot of the difference of T1 of normal appearing tissue in patients between
time-points. T1 relaxation times increase in WM and GM of the temporal lobe and in the WM
of the cerebellum.
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Figure A.4: Boxplot of the difference of T1 of normal appearing tissue of controls between
time-points. T1 relaxation times increase in WM and GM of the temporal lobe and in the WM
of the cerebellum.
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Figure A.5: Boxplot of T2 difference of normal appearing tissue in patients between time-
points. T2 relaxation times decrease in pallidum, putamen and WM of the parietal, frontal
and parietal lobes but increases in the caudate and MG of the frontal lobe.
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Figure A.6: Boxplot of T2 difference of normal appearing tissue in controls between time-
points. T2 relaxation times decrease in pallidum, putamen and WM of the parietal, frontal
and parietal lobes but increases in the caudate and MG of the frontal lobe.
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Figure A.7: Boxplot of T2* and MTR differences of normal appearing tissue between time-
points. T2* relaxation times increases in caudate, putamen and WM of the cerebellum, while
MTR decreases in the GM of the occipital lobe.
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The following figures illustrate the evolution of T1, T2 and MTRz-scores in MS lesions, as well
as in regions where lesions will appear or expand.
Figure A.8: Evolution of lesions among the different group based on qMRI combination.
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Figure A.9: Difference between T1, T2 and MTR in RRMS patients at TP1 in regions where
lesions appear at TP2 and T1, T2, MTR of the healthy normal appearing tissue in the corre-
sponding lobes (HC), and T1, T2, MTR at TP1 in the normal appearing tissue surrounding the
region (NA).
Figure A.10: Difference between T1, T2, T2* and MTR in RRMS patients at TP1 in regions
where lesions expand at TP2 and the T1, T2, T2* and MTR in healthy normal appearing tissue
in the corresponding lobes (HC) and T1, T2, T2* and MTR in the normal appearing tissue
surrounding the region (NA).
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